Method of treating depressed reticuloendothelial system function

Abstract

The present invention provides methods of treating adverse physiological effects associated with depressed reticuloendothelial system function comprising administering to a subject suffering from depressed reticuloendothelial system function an effective amount of a BPI protein product.

Description

BACKGROUND OF THE INVENTION

The present invention relates to therapeutic uses of bactericidal/permeability-increasing (BPI) protein products for the treatment of adverse effects associated with depressed reticuloendothelial system function generally and specifically for treatment of adverse effects associated with impaired liver function resulting from physical, chemical or biological insult to the liver.

BPI is a protein isolated from the granules of mammalian polymorphonuclear leukocytes (PMNs or neutrophils), which are blood cells essential in the defense against invading microorganisms. Human BPI protein has been isolated from PMNs by acid extraction combined with either ion exchange chromatography [Elsbach, J. Biol. Chem., 254:11000 (1979)] or E. coli affinity chromatography [Weiss, et al., Blood, 69:652 (1987)]. BPI obtained in such a manner is referred to herein as natural BPI and has been shown to have potent bactericidal activity against a broad spectrum of gram-negative bacteria. The molecular weight of human BPI is approximately 55,000 daltons (55 kD). The amino acid sequence of the entire human BPI protein and the nucleic acid sequence of DNA encoding the protein have been reported in FIG. 1 of Gray et al., J. Biol. Chem., 264:9505 (1989), incorporated herein by reference.

BPI is a strongly cationic protein. The N-terminal half of BPI accounts for the high net positive charge; the C-terminal half of the molecule has a net charge of −3. [Elsbach and Weiss (1981), supra.] A proteolytic N-terminal fragment of BPI having a molecular weight of about 25 kD has an amphipathic character, containing alternating hydrophobic and hydrophilic regions. This N-terminal fragment of human BPI possesses the anti-bacterial efficacy of the naturally-derived 55 kD human BPI holoprotein. [Ooi et al., J. Bio. Chem., 262: 14891-14894 (1987)]. In contrast to the N-terminal portion. the C-terminal region of the isolated human BPI protein displays only slightly detectable anti-bacterial activity against gram-negative organisms. [Ooi et al., J. Exp. Med., 174:649 (1991).] An N-terminal BPI fragment of approximately 23 kD, referred to as “rBPI 23 ,” has been produced by recombinant means and also retains anti-bacterial activity against gram-negative organisms. Gazzano-Santoro et al., Infect. Immun. 60:4754-4761 (1992).

The bactericidal effect of BPI has been shown to be highly specific to sensitive gram-negative species, while non-toxic for other microorganisms and for eukaryotic cells. The precise mechanism by which BPI kills gram-negative bacteria is not yet completely elucidated, but it is believed that BPI must first bind to the surface of the bacteria through electrostatic and hydrophobic interactions between the cationic BPI protein and negatively charged sites on LPS. LPS has been referred to as “endotoxin” because of the potent inflammatory response that it stimulates, i.e., the release of mediators by host inflammatory cells which may ultimately result in irreversible endotoxic shock. BPI binds to lipid A, reported to be the most toxic and most biologically active component of LPS.

In susceptible gram-negative bacteria, BPI binding is thought to disrupt LPS structure, leading to activation of bacterial enzymes that degrade phospholipids and peptidoglycans, altering the permeability of the cell's outer membrane, and initiating events that ultimately lead to cell death. [Elsbach and Weiss (1992), supra]. BPI is also capable of neutralizing the endotoxic properties of LPS to which it binds. Because of its gram-negative bactericidal properties and its ability to neutralize LPS, BPI can be utilized for the treatment of mammals suffering from diseases caused by gram-negative bacteria, such as bacteremia or sepsis. Bahrami et al., Int'l Endotoxin Soc. Meeting , Vienna, Austria (August 1992), disclose the use of a BPI protein for the treatment of haemorrhagic shock.

The cells of the reticuloendothelial system (“RES,” also referred to as the “mononuclear phagocytosis system”) include promonocytes and their precursors in the bone marrow, monocytes in the circulation and tissue macrophages including macrophages of the spleen, the liver (Kupffer cells), lungs (alveolar macrophages), connective tissue (histiocytes), bone (osteoclasts), skin (Langerhans cells), central nervous system (microglial cells) and serous cavities (pleural and peritoneal macrophages). Nolan, Gastroenterology; 69: 1346-1356 (1975) and Nolan, Hepatology, 1: 458-465 (1981) review the relationship between endotoxin of gut origin, the reticuloendothelial system and impairment of liver function resulting from e.g., viral infection and hepatic fibrosis as well as exposure to hepatotoxic chemical agents such as carbon tetrachloride. The fixed macrophages, or Kupffer cells, of the liver play a leading role in the RES by clearing and inactivating bacteria and bacterial particulates from the blood stream. In physiological situations, low levels of gut-derived endotoxin are presented to the liver and are detoxified by Kupffer cells of the hepatic RES. Partial hepatectomy results in fewer Kupffer cells and inability to clear and inactivate endogenous endotoxin adequately. Gross et al. J. Pediatric Surgery 20:320-323 (1985). In addition to these local effects of endotoxin which contribute to hepatic injury, systemic endotoxemia induces catabolic responses including an increased muscle breakdown. This results in increased plasma levels of glutamine which are associated with an increased uptake by the gut and a concomitant greater production of ammonia in the intestinal tract. This increased ammonia load, normally converted to urea in the liver, is insufficiently cleared after partial hepatectomy. It is believed that Kupffer cells are activated and release large amounts of cytokines including TNF and IL-1. See Nathan, J. Clin. Invest. 79: 319-326 (1987). Moreover, systemic endotoxemia triggers cytokine-release from mononuclear cells in other parts of the body, thus resulting in an amplified catabolic response.

Primary and secondary hepatic neoplasmata represent a significant health problem. Surgical intervention has become a valid therapeutic option but major hepatic resection is still accompanied by a high morbidity and mortality rate. Important postoperative complications include sepsis, hepatic failure and hemorrhage. Massive hepatectomy can also induce renal failure, respiratory failure and impaired myocardial function. Many of these complications closely resemble the effects of sepsis syndrome, van Leeuwen et al., Surgery 110: 169-175 (1991) disclose that after liver resection, systemic endotoxemia was provoked which was prevented by preoperative administration of the endotoxin-binding agents cholestyramine or lactulose. See also, J. of Medicine; Clinical, Experimental & Theoretical , 21(6):301-11(1990) which relates to administration of polymyxin B and attenuation of histological liver injury provoked by endotoxin administration after partial hepatectomy.

Thus, there exists a desire in the art for a treatment that reduces the adverse effects associated with depressed reticuloendothelial system function. In particular, there exists a need for a treatment that reduces the postoperative complications and mortality associated with major hepatic resection.

SUMMARY OF THE INVENTION

The present invention provides novel methods for the treatment of adverse effects associated with depressed reticuloendothelial system function and specifically treatment of adverse physiological effects associated with impaired liver function resulting e.g., from physical, biological and chemical insult to the liver. Conditions associated with impaired RES function include conditions which directly affect the liver including conditions associated with lowered blood flow to the liver via the portal vein or hepatic artery. Such conditions include but are not limited to, liver cirrhosis, liver transplantation, bile duct obstruction and depressed blood flow from the splenic bed.

More specifically, the invention provides methods for treating conditions associated with depressed reticuloendothelial system function comprising administering to a subject an amount of a BPI protein product effective to alleviate adverse physiological effects resulting from impaired capacity of the RES to clear and inactivate bacteria, bacterial particulates and endotoxin from circulation in the blood. The invention thus provides methods for treatment of endotoxin related sepsis-like conditions associated with impaired liver function resulting from physical (including surgical), chemical and biological (including bacterial and viral) insults to the liver. BPI administration according to the invention is particularly advantageous in the context of pre- and/or post-treatment of subjects undergoing liver surgery. Such methods are particularly preferred where the liver surgery comprises liver transplant or liver resection (hepatectomy) wherein transitory or permanent loss of RES function by Kupffer cells of the liver gives rise to adverse hemodynamic changes, leukocytosis and metabolic acidosis. Benefits resulting from treatment according to the invention include reduction in inflammatory response to liver resection and enhanced regenerative capacity of the remnant liver.

The invention further provides the use of a BPI protein product in the manufacture of a medicament for treatment of adverse physiological effects associated with depressed reticuloendothelial system function, including uses wherein the depressed reticuloendothelial function comprises diminished function of Kupffer cells of the liver such as when the diminished Kupffer cell function results from physical, chemical or biological insult to the liver. The methods of using BPI protein products in the manufacture of such medicaments include those wherein the BPI protein product is rBPI 23 , rBPI 21 , rBPI, rBPI 42 dimer and peptides as set out in SEQ ID NOS:3 through 224. The BPI protein products may also be used in the manufacture of such medicaments in conjunction with a pharmaceutically-acceptable diluent, adjuvant or carrier.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows proliferating cell nuclear antigen levels in liver of rats subjected to liver resection with or without rBPI 23 treatment;

FIG. 2 shows liver lipid content of rats subjected to liver resection with or without rBPI 23 treatment;

FIGS. 3 , 4 and 5 show mean arterial blood pressure (MAP), heart rate, and cardiac output (CO) of rats subjected to liver resection with or without rBPI 23 treatment; and

FIGS. 6 and 7 show rat plasma TNF and IL-6 levels of rats subjected to liver resection with or without rBPI 3 treatment.

DETAILED DESCRIPTION OF THE INVENTION

The invention is based on the discovery that administration of BPI protein products attenuates the adverse effects associated with depressed reticuloendothelial system function, particularly effects associated with impaired liver function. The dysfunction or partial resection of the hepatic phagocytic system, i.e. the Kupffer cells, results in reduced clearance of circulating potentially pathogenic particles. In addition, host injury increases intestinal permeability, thus promoting translocation of bacteria or their products (endotoxins) from the gut into the portal or lymphatic circulation. BPI protein products are shown herein to reduce the hemodynamic and metabolic alterations and the inflammatory responses that occur after partial hepatectomy, and also to improve the regenerative response of the liver as measured by liver cell proliferation.

Specifically contemplated by the invention is the treatment of adverse physiological effects resulting from physical, chemical and biological insult to the liver by administering BPI protein products to subjects exposed to such insults. Physical insult to the liver is exemplified by partial or total hepatectomy, such as accompanies transplantation, and trauma. Chemical insult is exemplified by results of exposure to hepatotoxic substances such as chloroform, glucosamine, carbon tetrachloride and ethanol. Biological insult is exemplified by infectious and non-infectious diseases such as viral hepatitis and chronic inflammatory hepatitis. The BPI protein products are preferably administered systemically, such as intravenously, intraperitoneally, or by intramuscular or subcutaneous injection.

As used herein, “BPI protein product” includes naturally and recombinantly produced BPI protein; natural, synthetic, and recombinant biologically active polypeptide fragments of BPI protein; biologically active polypeptide variants of BPI protein or fragments thereof, including hybrid fusion proteins and dimers; and biologically active polypeptide analogs of BPI protein or fragments or variants thereof, including cysteine-substituted analogs. The BPI protein products administered according to this invention may be generated and/or isolated by any means known in the art. U.S. Pat. No. 5,198,541, the disclosure of which is incorporated herein by reference, discloses recombinant genes encoding and methods for expression of BPI proteins including recombinant BPI holoprotein, referred to as rBPI or rBPI 50 and recombinant fragments of BPI. Co-owned, copending U.S. patent application Ser. No. 07/885,501 and a continuation-in-part thereof. U.S. patent application Ser. No. 08/072,063 filed May 19, 1993 and corresponding PCT Application No. 93/04752 filed May 19, 1993, which are all incorporated herein by reference, disclose novel methods for the purification of recombinant BPI protein products expressed in and secreted from genetically transformed mammalian host cells in culture and discloses how one may produce large quantities of recombinant BPI products suitable for incorporation into stable, homogeneous pharmaceutical preparations.

Biologically active fragments of BPI (BPI fragments) include biologically active molecules that have the same or similar amino acid sequence as a natural human BPI holoprotein, except that the fragment molecule lacks amino-terminal amino acids, internal amino acids, and/or carboxy-terminal amino acids of the holoprotein. Nonlimiting examples of such fragments include a N-terminal fragment of natural human BPI of approximately 25 kD, described in Ooi et al., J. Exp. Med., 174:649 (1991), and the recombinant expression product of DNA encoding N-terminal amino acids from 1 to about 193 or 199 of natural human BPI, described in Gazzano-Santoro et al., Infect. Immun. 60:4754-4761 (1992), and referred to as rBPI 23 . In that publication, an expression vector was used as a source of DNA encoding a recombinant expression product (rBPI 23 ) having the 31-residue signal sequence and the first 199 amino acids of the N-terminus of the mature human BPI, as set out in FIG. 1 of Gray et al., supra, except that valine at position 151 is specified by GTG rather than GTC and residue 185 is glutamic acid (specified by GAG) rather than lysine (specified by AAG). Recombinant holoprotein (rBPI) has also been produced having the sequence (SEQ ID NOS: 1 and 2) set out in FIG. 1 of Gray et al., supra, with the exceptions noted for rBPI 23 and with the exception that residue 417 is alanine (specified by GCT) rather than valine (specified by GTT). Other examples include dimeric forms of BPI fragments, as described in co-owned and co-pending U.S. patent application Ser. No. 08/212,132, filed Mar. 11, 1994, and corresponding PCT Application No. US95/03125 filed Mar. 13, 1995, the disclosures of which are incorporated herein by reference. Preferred dimeric products include dimeric BPI protein products wherein the monomers are amino-terminal BPI fragments having the N-terminal residues from about 1 to 175 to about 1 to 199 of BPI holoprotein. A particularly preferred dimeric product is the dimeric form of the BPI fragment having N-terminal residues 1 through 193, designated rBPI 42 dimer.

Biologically active variants of BPI (BPI variants) include but are not limited to recombinant hybrid fusion proteins, comprising BPI holoprotein or biologically active fragment thereof and at least a portion of at least one other polypeptide, and dimeric forms of BPI variants. Examples of such hybrid fusion proteins and dimeric forms are described by Theofan et al. in co-owned, copending U.S. patent application Ser. No. 07/885,911, and a continuation-in-part application thereof. U.S. patent application Ser. No. 08/064,693 filed May 19, 1993 and corresponding PCT Application No. US93/04754 filed May 19, 1993, which are all incorporated herein by reference and include hybrid fusion proteins comprising, at the amino-terminal end, a BPI protein or a biologically active fragment thereof and, at the carboxy-terminal end, at least one constant domain of an immunoglobulin heavy chain or allelic variant thereof.

Biologically active analogs of BPI (BPI analogs) include but are not limited to BPI protein products wherein one or more amino acid residues have been replaced by a different amino acid. For example, co-owned, copending U.S. patent application Ser. No. 08/013,801 filed Feb. 2, 1993 and corresponding PCT Application No. US94/01235 filed Feb. 2, 1994, the disclosures of which are incorporated herein by reference, discloses polypeptide analogs of BPI and BPI fragments wherein a cysteine residue is replaced by a different amino acid. A preferred BPI protein product described by this application is the expression product of DNA encoding from amino acid 1 to approximately 193 or 199 of the N-terminal amino acids of BPI holoprotein, but wherein the cysteine at residue number 132 is substituted with alanine and is designated rBPI 21 Δcys or rBPI 21 . Other examples include dimeric forms of BPI analogs; e.g. co-owned and co-pending U.S. patent application Ser. No. 08/212,132 filed Mar. 11, 1994, and corresponding PCT Application No. US95/03125 filed Mar. 13, 1995, the disclosures of which are incorporated herein by reference.

Other BPI protein products useful according to the methods of the invention are peptides derived from or based on BPI produced by recombinant or synthetic means (BPI-derived peptides), such as those described in co-owned and copending PCT Application No. US94/10427 filed Sep. 15, 1994 which corresponds to U.S. patent application Ser. No. 08/306,473 now U.S. Pat. No. 5,652,332 filed Sep. 15, 1994, and PCT Application No. US94/02465 filed Mar. 11, 1994, which corresponds to U.S. patent application Ser. No. 08/209,762, filed Mar. 11, 1994, which is a continuation-in-part of U.S. patent application Ser. No. 08/183,222, filed Jan. 14, 1994, which is a continuation-in-part of U.S. patent application Ser. No. 08/093,202 filed Jul. 15, 1993 (for which the corresponding international application is PCT Application No. US94/02401 filed Mar. 11, 1994), which is a continuation-in-part of U.S. patent application Ser. No. 08/030,644 filed Mar. 12, 1993, the disclosures of all of which are incorporated herein by reference. Illustrative endotoxin binding and neutralizing peptides include those set out in SEQ ID NOS:3 through 224.

Presently preferred BPI protein products include recombinantly-produced N-terminal fragments of BPI, especially those having a molecular weight of approximately between 21 to 25 kD such as rBPI 23 or rBPI 21 , or dimeric forms of these N-terminal fragments (e.g., rBPI 42 dimer). Additionally, preferred BPI protein products include rBPI and BPI-derived peptides.

The administration of BPI protein products is preferably accomplished with a pharmaceutical composition comprising a BPI protein product and a pharmaceutically acceptable diluent, adjuvant, or carrier. The BPI protein product may be administered without or in conjunction with known surfactants, other chemotherapeutic agents or additional known anti-microbial agents. A preferred pharmaceutical composition containing BPI protein products (e.g., rBPI, rBPI 23 ) comprises the BPI protein product at a concentration of 1 mg/ml in citrate buffered saline (5 or 20 mM citrate, 150 mM NaCl, pH 5.0) comprising 0.1% by weight of poloxamer 188 (Pluronic F-68, BASF Wyandotte, Parsippany, N.J.) and 0.002% by weight of polysorbate 80 (Tween 80, ICI Americas Inc., Wilmington. Del.). Another preferred pharmaceutical composition containing BPI protein products (e.g., rBPI 21 ) comprises the BPI protein product at a concentration of 2 mg/ml in 5 mM citrate, 150 mM NaCl, 0.2% poloxamer 188 and 0.002% polysorbate 80. Such preferred combinations are described in co-owned, co-pending PCT Application No. US94/01239 filed Feb. 2, 1994, which corresponds to U.S. patent application Ser. No. 08/190,869 filed Feb. 2, 1994 and U.S. patent application Ser. No. 08/012,360 filed Feb. 2, 1993, the disclosures of all of which are incorporated herein by reference.

The following illustrative example of practice of methods of the invention involves prophylactic administration of BPI protein products to alleviate postoperative complications attending liver resection.

EXAMPLE 1

Effect of BPI Protein Product on Hemodynamic and Metabolic Parameters of Rats Subjected to Liver Resection

In this example, the effect of a BPI protein product (rBPI 23 ) administered by a continuous intravenous infusion was determined on rats subjected to a 70% liver resection according to the general methods described by van Leeuwen et al., Surgery 110: 169-175 (1991). Specifically, male Wistar rats (230-250 g) received a 70% liver resection or a sham operation under light ether anesthesia, and were treated with either rBPI 23 (8 resected rats, 7 sham rats) or thaumatin a “control” protein having similar molecular weight and isoelectric point (8 resected rats, 8 sham rats). Specifically, the rats were treated with a first loading dose of either rBPI 23 or thaumatin at 1 mg/kg followed 20 minutes later by a second loading dose of rBPI 23 or thaumatin followed immediately by a continuous intravenous infusion of either rBPI 23 or thaumatin at 0.2 mg/kg/hr. Various physiological parameters were measured 4 hours after the resection or sham operation along with IL-6 levels which were determined using the B9 bioassay according to the methods of Helle et al., Eur. J. Immunol. 18:1535-1540 (1988). An alternative assay for IL-6 is described in Helle et al., J. Immunol. Meth. 138:47-56 (1991). The results of these assays are shown in Tables 1, 2 and 3 below.

Control resected rats demonstrated a significantly decreased mean arterial pressure and heart rate compared to control, sham-operated animals. These variables dramatically increased with BPI treatment in the resected rats. Blood pH was significantly decreased in the resected control group (p<0.05), whereas the leukocyte count and hematocrit were significantly increased compared to levels of control, sham-operated animals (p<0.005 and p<0.05, respectively). In the BPI treated resected rats, these parameters were restored to near sham levels.

Levels of IL-6, an important inflammatory mediator, were profoundly elevated in the resected control group compared to the sham control group and the sham BPI treated group. In contrast, the IL-6 levels of the BPI treated resected group were significantly reduced from those of the resected control group as shown in Table 3.

These results show that the early postoperative course following partial hepatectomy is characterized by substantial hemodynamic and metabolic changes. Perioperative infusion of rBPI 23 in rats prevented early postoperative hypotension and bradycardia, metabolic acidosis as well as leucocytosis, and also reduced IL-6 levels. These data show that systemic endotoxemia and/or bacteremia, possibly of gut origin, is a major cause of liver surgery postoperative hemodynamic and metabolic derangements including leukocytosis and metabolic acidosis and that administration of BPI protein products can prevent those conditions.

TABLE 1
Mean Arterial Pressure
(mm Hg)
	BPI	Control
	Resected	107.6 ± 4.9	74.1 ± 3.2
	Sham	99.2 ± 3.0	101.4 ± 4.0

TABLE 2
Heart Rate
(b/min)
	BPI	Control
	Resected	401 ± 10	306 ± 15
	Sham	372 ± 12	376 ± 14

TABLE 3
IL-6
(U/mL)
	BPI	Control
	Resected	517 ± 86	1234 ± 115
	Sham	214 ± 34	177 ± 29

EXAMPLE 2

Effects of BPI Protein Product on Liver Cell Proliferation and Metabolism of Rats Subjected to Liver Resection

The effects of administration of BPI protein product (rBPI 23 ) were determined on liver cell proliferation and liver metabolism of rats subjected to liver resection using procedures essentially as in Example 1. Male Wistar rats (230-250 g, Harlan CPB, Zeist, The Netherlands) were allowed to acclimatize to the laboratory environment for five days with free access to water and rat chow (Hope Farms, Woerden, The Netherlands). The animals were housed under standard environmental conditions with a 12-hr light/dark cycle. Chow was withdrawn on the evening before surgery. Surgery was performed between 9:00 and 11:00 am to avoid chronobiological variations.

The rats were randomized into different groups that underwent either a two-thirds partial hepatectomy (PHX) or a sham operation and were treated peri-operatively with either 0.9% saline or rBPI 23 . This resulted in the following three groups: (1) rats subjected to a sham operation and treated with saline (n=8); (2) rats subjected to partial hepatectomy and treated with saline (n=8); and (3) rats subjected to partial hepatectomy and treated with rBPI 23 (n=8). In addition, two groups of five animals each were used to assess the effects of rBPI 23 on sham-operated rats and the effects of a control protein thaumatin (an iso-electric, iso-kd protein) on partially hepatectomized rats.

Prior to the start of the treatment and surgical procedures, the animals were anaesthetized with ether and placed in a supine position. First, a loading dose of the drug or placebo was given via the tail vein: 1 mL 0.9% sodium chloride or 1 mg/kg rBPI 23 in 0.5 mL 0.9% saline. Then, a PE-50 catheter (Fisher Scientific, Springfield, N.Y.) was placed via the right jugular vein into the superior caval vein and subcutaneously tunnelled into the interscapular region. Through a spring wire (Instech Laboratories Inc., Plymouth Meeting, Pa.) this intravenous line was connected to a swivel (Instech Labs Inc.) and a micro-infusion pump (Harvard Apparatus, Boston, Mass.). Once the connection was made, a second loading dose of the drug or placebo comprising either 1 mL 0.9% saline or 2 mg/kg rBPI 23 in 1 mL 0.9% saline was injected slowly into the intravenous line. Immediately afterwards, a continuous infusion was started of 0.9% saline or 0.2 mg/kg/hr rBPI 23 at an infusion rate of 500 μL per hr.

The rats subsequently underwent either a two-third partial hepatectomy, according to the method of Higgins and Anderson Arch. Pathol., 12:186-202 (1931), or a sham operation. Resection of the median and left lateral lobes of the liver was performed with a single vicryl ligature that was carefully placed around the lobes using cotton wool sticks to prevent bleeding from the liver bed. Sham animals underwent a midline laparotomy and gentle manipulation and exteriorization of the median and left lateral lobes, without actual resection. The incision was closed in two layers by vicryl sutures. Within 20 minutes the animals regained consciousness and moved freely while continuing to receive their intravenous infusion. The animals received no food or oral fluids during the study. At 24 hours after surgery, each animal was reanesthetized using Ketamine HCl (50 mg/kg intraperitoneally) and the abdomen was reopened to remove the remnants of the liver. Liver samples up to 0.5 cm 3 were frozen immediately in liquid nitrogen or used in conventional histological studies.

Liver enzymes were evaluated as follows. Cryostat sections of constant 8 μm thickness were cut at −25 C. on a motor-driven cryostat (Bright, Huntingdon, UK), placed on clean glass slides and stored at −20° C. until use. Sections were allowed to dry for at least 5 min at 37° C. before incubation. Incubations were performed at 37° C. according to methods described in detail by Van Noorden and Frederiks, “Enzyme Histochemistry: a Laboratory Manual of Current Methods”. Oxford, Oxford University Press (1992). Alkaline phosphatase (EC 3.1.3.1) activity was demonstrated using a quantitative indoxyl-tetrazolium salt method. The incubation medium contained 18% (w/v) polyvinyl alcohol (PVA; weight average M. 70,000-1000,000; Sigma, St. Louis, Mo.) in Tris-HCl buffer (pH 9.0), 0.8 mM 5-bromo-4-chloro-3-indolyl phosphate (Boehringer, Mannheim, Germany) as substrate, 0.45 mM 1-methoxy phenazine methosulfate (1-mPMS, Serva, Heidelberg, Germany), 10 mM MgCl 2 , 5 mM sodium azide and 5 mM tetranitro blue tetrazolium salt (tetranitro BT; Serva, Heidelberg, Germany). Incubation lasted for 15 minutes and control incubations were performed in the presence of substrate and 10 mM tetramizole (Sigma). Glucose-6-phosphate dehydrogenase (EC 1.1.1.49) activity was demonstrated using a quantitative tetrazolium salt method. The incubation medium consisted of 100 mM phosphate buffer (pH 7.45) containing 18% (w/v) PVA, 10 mM glucose-6-phosphate (Serva) as substrate, 0.8 mM NADP + (Boehringer), 5 mM sodium azide, 0.45 mM 1-mPMS and 5 mM tetranitro BT. Sections were incubated for 10 minutes. Control incubations were performed in the absence of substrate and co-enzyme. Phosphogluconate dehydrogenase (EC 1.1.1.44) activity was demonstrated using a quantitative tetrazolium salt method. The medium was 100 mM phosphate buffer (pH 7.45) containing 18% (w/v) PVA. 8 mM 6-phosphogluconic acid (BDH Chemicals Ltd, Poole, Dorset, UK), 0.8 mM NADP + , 5 mM sodium azide, 0.45 mM 1-mPMS and 5 mM tetranitro BT. Incubation was performed for 10 min and control media lacked substrate. Afterwards, all sections were rinsed in 100 mM phosphate buffer (pH 5.3) at 60° C. to stop the reaction immediately and to remove all of the viscous medium from the sections. Sections were embedded in glycerin-gelatin.

The lipid content of the liver was assessed as follows. Sections were air-dried, treated briefly in 70% ethanol and incubated 30 minutes in a saturated Sudan Black B solution Merck, Darmstadt, Germany; 300 mg/100 mL 70% (v/v) ethanol). Afterwards, sections were rinsed twice in 70% ethanol, and once in 50% ethanol and distilled water before mounting in glycerin-gelatin. In order to measure total amounts of DNA and protein per unit tissue volume, sections were stained with the quantitative combined Feulgen-Naphthol Yellow S (NYS) staining method.

Cytophotometrical analysis of final reaction products was performed as described by Van Noorden and Frederiks, supra, with a Vickers M85a scanning and integrating cytophotometer (Vickers Instruments, York, England). Per rat, 10 readings were made in periporal and pericentral zones in each of 2 sections, both for test and control reactions. The relative integrated absorbance values were converted into mean integrated absorbance (MIA) by reference to a calibration curve. For specific absorbance due to enzyme activity, MIA values obtained in control reactions were subtracted from MIA values obtained in test reactions. For calculation of enzyme activity, MIA values were computed into μmoles of substrate converted per minute per cm 3 liver tissue by using the molar extinction coefficient of 19,000 for tetranitro BT-formazan.

Absorbance generated by dehydrogenase activity was measured at 557 nm using a 6.3× planachromatic objective (numerical aperture 0.20), a bandwidth setting of 65, a csanning spot with an effective diameter of 3.2 μm and a mask with a diameter of 63 μm. The area scanned per measurement was thus 3117 μm 2 . Formazan generated by alkaline phosphatase activity was measured at 557 nm using a 16× objective (numerical aperture 0.45), a bandwidth setting of 65, scanning spot with diameter 1.25 μm and a mask with diameter 50 μm. The total area scanned per measurement was 1963 μm 2 .

Sudan Black B stained sections were scanned at 595 nm using the same setting as for alkaline phosphatase activity measurements. Faulgen-NYS stained sections were analyzed cytophotometrically at 560 nm (Feulgen) and 430 nm (NYS) with a 6.3× objective (numerical aperture 0.20), bandwidth 65, a 3.2 μm scanning spot and a mask with a diameter of 159 μm and 95 μm respectively. The total area scanned for Feulgen stain was 19.856 μm 2 and for NYS, 7088 μm 2 .

For the demonstration of proliferating cell nuclear antigen PCNA), a modified streptavidin-biotin-diamino benzidine (DAB) method was used. All incubations were carried out at room temperature in a moist chamber, and all sections were rinsed in 0.01 M phosphate buffered saline (pH 7.4) between each step. Cryostat sections were dried overnight and fixed (for 2 minutes at room temperature) in 4% phosphate buffered formaldehyde (Merck), followed by upgraded and downgraded ethanol series. Sections were pre-incubated for 20 minutes with 10% normal goat serum, decanted and incubated for 60 minutes with a 1:100 dilution of mouse MAb PC 10 (Dakopatts, DAKO a/s, Glostrup, Denmark) directed against PCNA. Endogenous peroxidase activity was blocked using 0.3% (v/v) H 2 O2 and 0.1% (w/v) sodium azide for 15 min. Subsequently, sections were incubated with biotinylated rabbit-anti-mouse Ig at a 1:200 dilution, containing 10% human AB serum for 30 min, followed by an incubation with StreptABComplex (DAKO), prepared 30 minutes in advance using 0.5% (v/v) streptavidin, 0.5% (v/v) biotinylated horseradish peroxidase (HRP) and 10% (v/v) human AB serum. To detect peroxidase activity, sections were incubated for 10 minutes with 0.5 mg/mL DAB and 0.3% (v/v) H 2 O 2 in 50 mM Tris-HCl buffer (pH 7.6) and finally counterstained with haematoxylin. The PCNA index for periportal and pericentral areas was determined by analysis of the percentage of PCNA-positive liver cells out of 300 liver cells in both periportal and pericentral zones. For each rat, mean values of measurements were calculated for both periportal and pericentral zones. Results are expressed as means±standard error of the means per group of animals. Statistical analysis was performed by the non-parametric Mann-Whitney U Test. A p-value of less than 0.05 (two-tailed) was considered significant.

PCNA expression is displayed in FIG. 1 . In sham-operated animals, cell proliferation was virtually absent. In partially hepatectomized animals, there was a high rate of cell proliferation 24 hours post-surgery, particularly in the periportal zones. Treatment with rBPI 23 significantly increased liver cell proliferation, as indicated by PCNA expression, in both hepatocytes and sinusoidal cells in both zones of liver lobules.

Lipogenesis and lipid accumulation in the liver is correlated to liver damage and reduced regenerative capacity. Liver lipid content assessments are shown in FIG. 2 . Partial hepatectomy induced a 5-fold lipid accumulation in liver, compared to the sham-operated animals (p<0.001). Treatment with rBPI 23 , treatment significantly reduced lipid content by 20-30% (p<0.05). Lipid content was always higher periportally than pericentrally.

Treatment with rBPI 23 had no effect on alkaline phosphatase, glucose-6-phosphate dehydrogenase or phosphogluconate dehydrogenase activity. After partial hepatectomy, alkaline phosphatase (AP) activity in bile canalicular membranes was significantly increased both periportally (p<0.005) and pericentrally (p<0.001) compared to sham-operated animals. Predominant AP activity in partially hepatectomized rats was in pericentral zones, compared to periportal zones in sham-operated rats. In addition, AP activity was observed at the sinusoidal membranes of hepatocytes in hepatectomized rats, but not in sham-operated animals. Glucose-6-phosphate dehydrogenase (G6PD) activity was significantly decreased at 24 hr after partial hepatectomy compared with sham-operated rats (p<0.001 periportally; p<0.01 pericentrally). In addition, the higher periportal G6PD activity observed in sham-operated animals had disappeared. Phosphogluconate dehydrogenase (PGDH) activity, which was always higher pericentrally than periportally, was markedly decreased in partially hepatectomized rats compared with sham-operated animals.

Cytophotometric measurements of enzyme activity or lipid content did not need correction because the ratios of total DNA over total protein were similar in all periportal and pericentral zones of all animals. Partially hepatectomized rats that received thaumatin showed no significant difference from partially hepatectomized rats that received saline. Moreover, infusion of rBPI 23 or thaumatin compared to infusion of saline had no significant effects on the measured parameters in sham-operated animals (data not shown).

These results show that rBPI 23 treatment stimulated liver cell proliferation and reduced lipid accumulation after partial hepatectomy.

EXAMPLE 3

Effects of BPI Protein Product on the Local Inflammatory Response of Rats Subjected to Liver Resection

The effects of a BPI protein product, rBPI 23 , were determined on the local inflammatory response of rats subjected to liver resection according to the procedure described in Example 2. In particular, effects on infiltration of immune cells and expression of major histocompatibility complex (MHC) class II antigens of macrophages (a macrophage activation marker) in the remnant liver were studied using immunohistochemical techniques.

The rats were divided into three groups: (1) rats that underwent a sham operation with saline treatment (n=8); (2) rats that underwent partial hepatectomy with saline treatment (n=8); and (3) rats that underwent partial hepatectomy with rBPI 23 treatment (n=8). Before catheter insertion, the rats were given a loading dose of 0.5 mL 0.9% saline or 1 mg/kg rBPI 23 in 0.5 mL buffer solution (containing 20 mM sodium citrate, 150 mM sodium chloride; pH 5) via the tail vein. After catheterization, the rats were administered a second loading dose of either 1 mL 0.9% saline or 2 mg/kg rBPI 23 in 1 mL (0.5 mL buffer solution plus 0.5 mL 0.9% (w/v) NaCl). Immediately thereafter the rats were administered 0.9% saline or 0.2 mg/kg/hr rBPI 23 by continuous infusion at a rate of 500 μL per hr, which 'was continued for a 24-hour period. After 24 hours, liver samples were obtained as described in Example 2.

Alkaline phosphatase (AP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin and glucose serum levels were assessed by automated laboratory analysis. Ammonia levels were assayed by a standard enzymatic method. Sections of paraffin-embedded liver samples were subjected to conventional histology. All sections were read in a blinded fashion. Polymorphonuclear neutrophils (PMNs) were stained with chloracetate-esterase. Mast cells were stained using a Toluidine Blue O staining procedure. Proliferating cell nuclear antigen was also measured using the procedures described in Example 2.

Immunohistology was performed on the liver samples as follows. Incubations were carried out at room temperature in a moist chamber, and all sections were rinsed in 0.01 M phosphate buffered saline (PBS), pH 7.4, between each step, unless otherwise specified. Cryostat sections were air-dried for 30 minutes, fixed in acetone (for 7 minutes at 4° C.) and air-dried again (30 minutes) before incubation for 60 minutes with monoclonal antibodies (MAb) ED 1, ED 2 or OX 3 (Serotec, Hilversum, Netherlands) diluted 1:500 in PBS containing 0.2% (w/v) bovine serum albumin (BSA). MAb ED 1 recognizes a cytoplasmic antigen in monocytes and the various types of macrophage populations. MAb ED 2 recognizes membrane antigens of resident macrophages. MAb OX 3 is directed against a polymorphic determinant of the human MHC class II antigen (rat Ia antigen). Sections were then incubated for 30 minutes with rabbit-anti-mouse IgG peroxidase (Dakopatts, Copenhagen, Denmark) diluted 1:200 in PBS/BSA containing 1% (v/v) normal rat serum to reduce non-specific staining. Afterwards, sections were stained for peroxidase activity for 10 minutes using, 1 mM 3-amino-9-ethylcarbazole (AEC, Sigma, St. Louis, Mo., USA) dissolved in 5% (v/v) dimethyl formamide (DMF) and 0.01% (v/v) H 2 H 2 in 50 mM acetate buffer (pH 4.9). Finally, after rinsing in distilled water, sections were counterstained with hematoxylin for 1 minute and rinsed thoroughly before mounting in glycerol jelly.

To assess the composition of the hepatic mononuclear phagocytic cell pools, sections stained with mAb ED 1 (a marker for monocytes and all macrophage populations) were compared to consecutive sections stained with ED 2 (a marker for resident macrophages). After sham operation, the majority of these macrophages were both ED 1-positive (ED 1+) and ED 2-positive (ED 2+) and, thus, were predominantly Kupffer cells. After partial hepatectomy, an increase in the number of ED 1+ cells was observed compared to sham-operated rats. In partially hepatectomized rats, far more macrophages were ED 1+ than ED 2+, particularly in periportal areas, indicating an increase in the number of non-resident macrophages and monocytes. Livers of partially hepatectomized rats treated with rBPI 23 had fewer ED 1+ cells compared to saline-treated rats.

Expression of MHC class II antigen (an indicator of antigen presentation) was evaluated by immunohistochemical staining using mAb OX 3. Following partial hepatectomy, an increase in OX 3+ cells, predominantly in periportal areas, was observed compared to the sham-operated group. This increase in OX 3+ cells was not observed in livers from partially hepatectomized animals treated with rBPI 23 .

Conventional histological examination showed that, at 24 hours after partial hepatectomy, increased numbers of PMNs were found predominantly in periportal areas. Infrequent aggregates of PMNs in close contact with small patches of necrosis were also found. In partially hepatectomized animals treated with rBPI 23 , fewer PMNs were found periportally and virtually no PMNs were found in other areas, and no aggregates of PMNs or necrosis were observed. In all groups of animals only few mast cells were found, mainly adjacent to larger vessels.

PCNA values (means±standard error) are shown in Table 4 below. Liver cells of sham-operated rats expressed virtually no PCNA. At 24 hours after partial hepatectomy, a larger number of cells express PCNA, predominantly in periportal zones. Treatment of partially hepatectomized rats with rBPI 23 led to a significant increase in liver cell proliferation both periportally (p<0.01) and pericentrally (p<0.01).

Serum levels of measured parameters known to be related to liver function are depicted in Table 5. After 24 hours, circulating levels of alkaline phosphatase, AST, ALT and ammonia were significantly increased following partial hepatectomy compared to sham operated rats (p<0.0005, p<0.0005, p=0.0005 and p=0.01, respectively). Bilirubin levels were only slightly elevated following partial hepatectomy, though significantly higher than in the sham operated group (p=0.001). In addition, glucose levels were significantly lower then those found in sham animals (p<0.001). In the rBPI 23 treated partially hepatectomized animals, AST and ALT levels were significantly reduced (p<0.05 vs. untreated) but still elevated compared to sham-operated rats. Ammonia levels were also lower in animals treated with rBPI 23 (p=0.1) and were close to those in the sham-operated rats. Other measured parameters of liver function (AP, bilirubin and glucose) were not affected by treatment with rBPI 23 .

These results show that, following partial hepatectomy, there is a local inflammatory response. This inflammatory response is characterized by a profound influx of mononuclear phagocytes and a moderate infiltration of PMNs and coincides with increased serum levels of markers of liver dysfunction (AST, ALT, ammonia), implying damage of liver parenchyma by these reactions. There is also a higher proportion of macrophages expressing Ia antigens, which are indicative of activation and possibly antigen-presentation. Treatment with rBPI 23 reduced hepatic inflammation and partially prevented liver failure. In addition, liver cell proliferation liver regeneration (e.g., as assessed by PCNA expression) was significantly enhanced by rBPI 23 treatment.

TABLE 4
Expression of proliferating cell nuclear antigen
	periportal	pericentral
	sham operation	0.5 ± 0.2	0
	with saline
	treatment
	partial	13.0 ± 3.0	3.6 ± 1.4
	hepatectomy with
	saline treatment
	partial	28.9 ± 3.2**	13.4 ± 3.2*
	hepatectomy with
	rBPI 23 treatment
	*p < 0.05 for differences between treated and untreated partially hepatectomized rats, using the non-parametric Mann-Whitney U Test.
	**p < 0.01 for differences between treated and untreated partially hepatectomized rats, using the non-parametric Mann-Whitney U Test.

TABLE 5
Biochemical parameters of liver function
	AP	AST	ALT	bilirubin	ammonia	glucose
	(units/L)	(units/L)	(units/L)	(umol/L)	(umol/L)	(mmol/L)
sham operation	74 ± 5	60 ± 6	19 ± 5	1 ± 0	59 ± 5	10.1 ± 0.4
saline treatment
partial	219 ± 24	803 ± 104	633 ± 94	6.0 ± 1.2	106 ± 12	6.6 ± 0.2
hepatectomy,
saline treatment
partial	271 ± 28	478 ± 58*	337 ± 68*	4.4 ± 0.6	70 ± 6*	6.8 ± 0.2
hepatectomy,
rBPI 23
treatment
*p < 0.05 for differences between treated and untreated partially hepatectomized rats, using the non-parametric Mann-Whitney U Test.

EXAMPLE 4

Effects of BPI Protein Product on Hemodynamic and Metabolic Parameters of Rats Subjected to Liver Resection

The effects of administration of a BPI protein product (rBPI 23 ) were determined on hemodynamic and metabolic parameters of rats subjected to liver resection, using the general procedure described in Example 2 above. The rats were divided into four treatment groups: (1) rats receiving a sham operation and thaumatin treatment (SH-CON, n=20); (2) rats receiving a sham operation and rBPI 23 treatment (SH-BPI, n=20); (3) rats receiving a partial hepatectomy and thaumatin treatment (PHX-CON, n=22); and (4) rats receiving a partial hepatectomy with rBPI 23 treatment (PHX-BPI, n=22).

Specifically, treatment was administered as follows. First, a loading dose of either 1 mg/kg rBPI 23 or 1 mg/kg thaumatin in 0.5 mL buffer solution (containing 20 mM sodium citrate, 150 mM sodium chloride; pH 5.0), was given via the tail vein. After catheterization, a second loading dose of either 2 mg/kg rBPI 23 or thaumatin in 1 mL (0.5 mL buffer solution plus 0.5 mL 0.9% (w/v) NaCl), was administered. Immediately thereafter, a continuous infusion of 0.2 mg/kg/hr rBPI 23 or thaumatin was begun at an infusion rate of 500 μL per hr throughout the observation period. All rats moved freely except for the animals used for frequent blood sampling.

Serial blood samples during a 4-hour period were obtained from six animals in each group. Small quantities of arterial blood (250 μL) were drawn from a small arterial line in the femoral artery, at a time before (for a baseline) and at 1, 2, 3 and 4 hours after the operation for determination of plasma levels of cytokines, hematocrit (at 4 hours only) and for indirect determination of endotoxin content. Heparinized blood samples were immediately placed on ice, and plasma was obtained by centrifugation of blood for 15 minutes at 1500 g at 4° C. All plasma samples were harvested in a laminar flow cabinet to prevent contamination, and stored in aliquots at −70 C. until tested.

Hemodynamic parameters were measured for eight animals in each group at 4 hours post-operation. Blood samples were not taken until after 4 hours, to minimize interference with the hemodynamic parameters. After 4 hours, arterial blood samples were taken for chemical blood analysis as well as determination of plasma levels of TNF and IL-6. Cytokine levels assessed in these animals were subsequently compared with those of the animals from which samples had been taken more frequently. In the remaining animals of each group (SH-CON and SH-BPI, each n=6; PHX-CON and PHX-BPI, each n=8), treatment was continued for a 24-hour period. After 24 hours, these animals were reanesthetized, a small arterial blood sample (200 μL) was taken for comparative IL-6 analysis, and the animals were then sacrificed and the lungs were removed for histological studies. Sections of the tissues were made by conventional methods and chloracetate-esterase (Lederstain) was used for staining of polymorphonuclear neutrophils (PMNs).

For hemodynamic measurements, animals were anesthetized using Ketamine HCL (50 mg/kg intraperitoneally) and placed in the supine position on a heating pad that maintained rectal temperature at 37 C. The trachea was intubated with a small polyethylene tube (PE-240; Fisher Scientific) to facilitate breathing. The right carotid artery and left femoral artery were cannulated using PE-50 tubing. Both catheters were connected to P23Db Statham pressure transducers to monitor placement of the carotid catheter into the left cardiac ventricle and to measure femoral artery blood pressure. Following these procedures, rats were allowed to stabilize for 20 minutes. Prior to the hemodynamic measurements, 150 μL of blood was drawn from the femoral artery for hematologic, pH and blood gas analysis. Thereafter, mean arterial blood pressure (MAP) and heart rate were recorded continuously during 1 minute.

Cardiac output measurements were performed using the radiolabeled microsphere method of Malik et al.. J. Appl. Physiol., 40:472-475 (1976). Briefly, 0.7 mL of a 0.9% NaCl suspension containing 1.0-1.5×10 5 microspheres labeled with 46 Sc (New England Nuclear, Boston, Mass.) were injected into the left ventricle over a period of approximately 20 seconds. A reference blood sample was obtained form the femoral artery by a calibrated roller pump starting 5 seconds before microsphere injection, at a rate of 0.50 mL/minute for 90 seconds. Following the microsphere injection, arterial blood pressure was recorded once more, to assure that the procedure had not been performed during significant hemodynamic changes and had not caused significant changes. After hemodynamic monitoring was completed, blood samples were drawn, the animals were sacrificed, and the heart was dissected free and weighed. Radioactivity was counted in a well type gamma counter (LKB-1280, Ultrogamma, Wallac, Turku, Finland). Count rates were corrected for natural background and counter dead time. Cardiac output (CO) was calculated according to the equation: CO=Fa (Qtot/Qa), where Fa is reference flow, Qtot is the total injected radioactivity and Qa is the radioactivity in the reference sample. Reference flow was computed from the weight of blood in the sample syringe (assuming a whole blood density of 1.069 g/mL) and the duration of withdrawal. Arterial blood flow to the heart via coronary arteries was calculated using the equation F=Fa(Qo/Qa), where Qo is the count rate in the organ to be measured.

Acid base balance was measured as part of a blood gas analysis using a commercial blood gas analyzer (ABL 330, Radiometer, Copenhagen, Denmark). Hemoglobin, hematocrit, total white blood cell (WBC) numbers as well as chemical parameters were analyzed by automated laboratory analysis. Ammonia levels were assayed by a standard enzymatic method.

Biologic TNF activity was measured as described by Espevik and Nissen-Meyer, J. Immunol. Methods, 95:99-105 (1986), using the murine fibrosarcoma WEHI 164 clone 13 cell line. Briefly, 4×10 4 WEHI cells/100 μL were incubated in RPMI 1640 containing 100 U/mL penicillin, 100 μl/mL streptomycin, L-glutamine, 10% (v/v) fetal calf serum (FCS), and 1 μg/mL Actinomycin D in the presence of serial dilutions of samples to be tested. After 18 h at 37° C., cytotoxicity was assessed with the MTT (3-(4,5-dimethylthazol-2-yl)-2.5-diphenyl tetrazolium bromide) method of Hansen et al., J. Immunol. Methods, 119:203-210 (1989). Serial dilutions of samples to be tested were compared to a standard curve of recombinant mouse TNF and expressed as units per mL. One unit per mL is the amount of TNF that kills 50% of the cells. The lower detection limit of the assay at the dilutions of samples used was 1 unit per mL.

IL-6 bioactivity was measured with the murine hybridoma B cell line B9 [Hele et al., Eur. J. Immunol., 18:1535-1540 (1988)]. Briefly, 5000 B9 cells in 200 μL flat-bottom wells were grown in Iscove's modified Dulbecco's medium (IMDM) containing 100 U/mL penicillin, 100 μg/mL streptomycin, 5×10 −5 M 2-mercaptoethanol, and 5% (v/v) FCS in the presence of serial dilutions of samples to be tested. After 68 to 72 hours, cells were labeled with 7.4 kBq of [ 3 H]thymidine (74 Gbq/mmol) and thereafter the radioactivity incorporated in the nuclei was counted. Results were compared with a standard curve of natural IL-6 from cultured human monocytes simulated with endotoxin, and expressed as units per mL. One unit per mL of IL-6 is the concentration that induces half-maximal thymidine incorporation in the assay. The lower detection limit of the assay of the dilutions of samples used was 10 units per mL.

The presence of biologically active endotoxins in rat plasma was assessed by measuring the ability of the rat plasma to induce production of pro-inflammatory cytokines by human mononuclear cells. Whole blood of healthy human volunteers was cultured at a final dilution of 1:10 in 200 μL flat-bottom wells in endotoxin-free IMDM containing 100 U/mL penicillin, 100 μL/mL streptomycin, and 0.1% (v/v) endotoxin-free FCS, in the presence of serial dilutions of rat plasma samples to be tested. Each sample was tested alone and in the presence of either 5 μg/mL α CD14 mAb (αCD14.22; CLB, Amsterdam, The Netherlands), 2 μg/mL rPBI 23 or 2 ng/mL Polymyxin B (Sigma, St. Louis, Mo., USA). After incubation for 18 hours at 37° C., culture supernatants were harvested and stored at −70° C. until tested for the presence of cytokines. As a control, normal rat plasma containing LPS ( E. coli 055:B5) at concentrations of 0.1 to 1000 pg/mL was tested under similar conditions.

TNF-α in the supernatant was measured by a sandwich-type ELISA using two monoclonal antibodies (CLB, Dept. Immune Reagents, Amsterdam, Netherlands) raised against recombinant human TNF-α (Chiron Corp., Emeryville, Calif.). One mAb (mAb CLB-TNFα-7) was used for coating at a concentration of 2 μg/mL. The other mAb (mAb CLB-TNFα-5) was biotinylated and used in combination with streptavidin polymerized horseradish peroxidase conjugate (CLB, Dept. Immune Reagents, Amsterdam, Netherlands) to detect bound TNF-α. For each of the cytokines measured, polymerized horseradish peroxidase conjugated to streptavidin was used to quantify bound biotinylated anticytokine antibodies. Stimulated human mononuclear cell supernatant was used as a standard for the assay. The amount of TNF-α present in this supernatant was assessed by comparison with purified recombinant human TNF-α. Results were expressed as pg/mL by reference to this standard.

IL-6 concentration in the supernatant was quantified with an ELISA modified from Helle et al., J. Immunol. Methods, 38:47-56 (1991). Briefly, purified monoclonal anti-human-IL-6 antibody (mAb CLB-IL6-16) was used as a capture antibody, and biotinylated sheep antibodies in combination with streptavidin polymerized horseradish peroxidase conjugate were used to detect bound IL-6. Results were expressed as pg/mL by reference to a standard consisting of recombinant human IL-6.

IL-8 was measured with a sandwich-type ELISA modified from Hack et al., Infect. Immunity, 60:2835-2842 (1992). Briefly, monoclonal anti-human-IL-8 antibody (mAb CLB-IL8/1) and biotinylated affinity purified sheep anti-IL-8 antibodies were used as capture and detecting antibodies, respectively. Results were compared with those obtained with dilutions of a standard recombinant human IL-8 and expressed as pg/mL.

To assess donor-dependent variability, each sample was assayed in duplicate, and each duplicate trial was repeated with blood from a different donor. All ELISAs used had inter-assay variation coefficients of less than 15%, estimated from the variation of dose-response curves obtained on at least three different days over a three-month period. All supernatants were tested within one assay procedure to minimize the inter-assay variation of each cytokine.

The data are expressed as means±standard error of means (SEM). The non-parametric Mann-Whitney U Test was used to assess the significance of differences between groups. Analysis of variance (ANOVA) for repeated measures was used to assess significant changes in parameters in the course of the observation period. A difference was considered significant at p<0.05 (two-tailed). The Mann-Whitney U Test was then used to determine the significance of the differences between groups. Data were analyzed with a commercial statistical package (Stat-View®; Abacus Concepts, Inc., Berkeley, Calif.).

Mean arterial blood pressure (MAP), heart rate, and cardiac output (CO) of the different treatment groups are shown in FIGS. 3 , 4 and 5 . Compared to sham-operated (SHAM) rats, the partially hepatectomized (PHX) rats showed significant decreases in MAP, heart rate and CO of 27%, 19% and 43% (p<0.005 for each of the three parameters), respectively, at 4 hours after surgery. Treatment of PHX rats with rBPI 23 prevented these changes in MAP, heart rate and CO, resulting in values equivalent to those of sham animals.

The blood supply to the heart tissue remained unchanged following partial hepatectomy: 4.76±1.22 and 4.93±0.67 mL/min (or 6.07±1.61 and 6.72±0.88 mL/min per gram of heart tissue) for SHAM and PHX animals, respectively. Infusion of rBPl 23 had no significant effect on these parameters, neither in SHAM nor PHX animals. The hypotension in the PHX animals apparently induced a compensatory redistribution of blood flow, since these animals showed a 62% increase in the proportion of CO that was distributed to the heart tissue via the coronary arteries (p<0.05). In rBPI 23 -treated PHX animals, CO distribution to the heart tissue was similar to that of the SHAM group.

The lungs, which are frequently involved in systemic inflammatory reactions, were examined for possible inflammatory changes. PHX animals showed a significant number of PMNs infiltrating the lungs at 24 hours after the operation, which was largely abrogated by rBPI 23 treatment. Furthermore, in the PHX group, some marginating neutrophils and intravascular accumulation of PMNs were found in the lungs, whereas rBPI 23 -treated PHX rats showed virtually none of these morphologic changes. Neither control group (sham-operated with or without rBPI 23 ) had an inflammatory infiltrate in the lungs.

Chemistry data at 4 hours after the surgical procedure are displayed in Table 6. For PHX rats, hemoglobin concentration and hematocrit both increased (p<0.05), and arterial blood pH and glucose levels significantly declined (p<0.05 and p<0.01, respectively), compared to SHAM values. In addition, creatinine and urea (both p<0.05), as well as hepatic enzymes (AST and ALT), bilirubin, ammonia and total WBC numbers were increased (all p<0.005) at 4 hours after liver resection compared to SHAM rats. Treatment of PHX rats with rBPI 23 resulted in significantly reduced creatinine levels and total WBC numbers, though the latter were still significantly higher than SHAM levels. Treatment with rBPI 23 also reduced the fall in glucose levels and prevent the fall of pH in PHX rats. Conversely, the pH in these animals was slightly higher than in SHAM animals. Urea levels in rBPI 23 -treated animals were lower than those of the thaumatin-treated PHX group, but this difference did not reach statistical significance. Treatment with rBPI 23 had no significant effect on changes in hepatic enzymes. bilirubin and ammonia, as determined 4 hours after surgery.

Rat plasma TNF and IL-6 levels are shown in FIGS. 6 and 7 , respectively. In these figures, values for thaumatin-treated PHX rats appear as open squares, values for rBPI 23 -treated PHX rats appear as filled squares, values for thaumatin-treated SHAM rats appear as open circles, and values for rBPI 23 -treated SHAM rats appear as filled circles. Sham-operated animals showed a modest increase in TNF levels at t=1 hour that lasted for at least 2 hours. From t=4 hours on, levels of TNF were no longer detectable in the plasma or were near the detection limit of the assay. In thaumatin-treated PHX rats, a sharp rise in TNF levels was found at t=2 hours (74.8±16.1 U/mL; p<0.01 vs SHAM), which rapidly declined thereafter to reach values of 6.8±2.3 U/mL at 4 hours after the resection. Conversely, in the rBPI 23 -treated PHX animals, plasma levels of TNF were undetectable in all but two animals, which had detectable TNF concentrations at only one time point (t=3 h; 1.9 and 2.9 U/mL). The difference in TNF concentrations between rBPI 23 -treated and thaumatin-treated PHX animals was highly significant at t=2 hours (<0.001) and significant at subsequent time points (p<0.01). During the entire observation period, TNF levels of rBPI 23 -treated PHX rats also were lower than those of SHAM rats.

Following the sham procedure, an early though moderate rise of IL-6 was found from t=1 hour onwards. In thaumatin-treated PHX rats, Il-6 levels demonstrated a steady increase from t=2 hours onwards, reaching peak levels of 2119±396 U/mL at t=4 hours (p<0.005 vs SHAM). Treatment of PHX rats with rBPI 23 yielded significantly lower levels of IL-6 compared to control treatment (p<0.005 at t=4 hours, and p<0.05 at t=2 hours and t=3 hours).

The cytokine-inducing activity of rat plasma was also measured. As a standard, 1 pg/mL LPS added to human whole blood resulted in a TNF-α concentration in the supernatant of 145±38 pg/mL in the presence of 15% (v/v) normal rat plasma. Addition of αCD14 mAb, rBPI 23 and to a lesser extent polymyxin B blocked cytokine release (of TNF-α, IL-6 and IL-8). Plasma of SHAM rats induced TNF-α levels ranging from 117 to 255 pg/mL. Addition of αCD14 mAb, rBPI 23 or polymyxin B with SHAM plasma did not significantly affect TNF-α, IL-6 and IL-8. Plasma of thaumatin-treated PHX rats taken at 1 and 2 hours after the resection induced significantly higher levels of human TNF-α in the supernatant compared to baseline plasma samples (both p<0.05) or plasma of SHAM rats (both p<0.05). TNF-α levels induced by PHX rat plasma taken at t=1 hours were consistently higher than those of PHX rat plasma taken at t=2 hours. In contrast, no significant increase in supernatant TNF-α levels was measured when plasma of rBPI 23 -treated rats, taken at t=1 hours or t=2 hours (data not shown) was tested, the levels being the same as baseline and nearly equal to the levels found with plasma of sham-operated rats.

When αCD14 mAb or rBPI 23 was added with plasma of thaumatin-treated PHX rats, the supernatant TNF-α concentrations were reduced to levels induced by baseline plasma (both p<0.05, compared to levels induced by PHX plasma alone). Addition of polymyxin B to the PHX plasma samples taken at 1 or 2 hours also resulted in reduction of TNF-α levels, though not reaching statistical significance. Addition of αCD14 mAb or polymyxin B with plasma of rBPI 23 -treated rats did not alter the levels of TNF-α, while addition of rBPI 23 slightly but not significantly reduced these levels.

Similar results were obtained when IL-6 or IL-8 were measured in the culture supernatants. Again, plasma of thaumatin-treated PHX rats taken at t=1 hour and t=2 hours yielded significantly higher levels of these cytokines in the supernatant than the plasma of rBPI 23 -treated PHX rats. These elevated levels could be diminished by adding αCD14 mAb, rBPI 23 and, to a lesser extent, polymyxin B to the culture (data not shown).

These results show that administration of rBPI 23 completely prevented cardiac failure following partial hepatectomy, as illustrated by preservation of blood pressure, cardiac output and heart rate. Treatment with rBPI 23 also abrogated or diminished other metabolic alterations indicative of a systemic inflammatory response, such as release of the cytokines TNF and IL-6, increased creatinine and urea (indicative of renal dysfunction), metabolic acidosis, inflammatory changes in the lungs, altered white blood cell count and glucose levels, and an increase in hematocrit (indicating hypovolemia presumably due to an increase in vasopermeability).

TABLE 6
Values at
4 hours post-
surgery	SHAM-CON	SHAM-BPI	PHX-CON	PHX-BPI
Hgb	7.8 ± 0.4	7.6 ± 0.2	9.0 ± 0.3*	7.8 ± 0.03
(mmol/L)
Hct	0.41 ± 0.02	0.40 ± 0.01	0.45 ± 0.02*	0.40 ± 0.01
WBC	4.9 ± 0.9	5.2 ± 0.5	12.0 ± 1.5**	8.0 ± 0.9#
(x10E9/L)
arterial pH	7.33 ± 0.01	7.31 ± 0.01	7.26 ± 0.03*	7.39 ± 0.02#
creatinine	33 ± 2	34 ± 2	43 ± 4*	31 ± 2
(umol/L)
urea	6.2 ± 0.6	5.7 ± 0.5	9.4 ± 0.5*	8.0 ± 0.4
(mmol/L)
AST	66 ± 2	73 ± 4	622 ± 64**	689 ± 90**
(U/L)
ALT	21 ± 1	28 ± 3	433 ± 69**	462 ± 128**
(U/L)
bilirubin	2 ± 0.1	2 ± 0.3	9 ± 1.4**	10 ± 2.7**
(umol/L)
ammonia	104 ± 14	92 ± 7	227 ± 16**	198 ± 13**
(umol/L)
glucose	8.3 ± 0.4	8.1 ± 0.4	6.6 ± 0.4*	7.3 ± 0.5
(mmol/L)
*p < 0.05 vs. SH-CON or SH-BPI.
**p < 0.005 vs. SH-CON and SH-BPI.
#p < 0.05 vs. SH-CON or SH-BPI, and also p < 0.05 vs. PHX-CON.

Numerous modifications and variations in the practice of the invention are expected to occur to those skilled in the art upon consideration of the presently preferred embodiments thereof. For example, while the above illustrative example establishes that beneficial effects attend treatment with BPI protein products as an adjunct to performance of liver resection, similar effects are expected to attend use during and after liver transplant surgery. In addition, adverse effects of biological and chemical insults to the liver are expected to be similarly alleviated by treatment with BPI protein products. Moreover, the examples demonstrate the utility of BPI protein products at addressing insults generally to other members of the reticuloendothelial system. Consequently, the only limitations which should be placed upon the scope of the invention are those which appear in the appended claims.

224 1813 base pairs nucleic acid single linear cDNA CDS 31..1491 mat_peptide 124..1491 misc_feature “rBPI” 1CAGGCCTTGA GGTTTTGGCA GCTCTGGAGG ATG AGA GAG AAC ATG GCC AGG GGC 54 Met Arg Glu Asn Met Ala Arg Gly -31 -30 -25CCT TGC AAC GCG CCG AGA TGG GTG TCC CTG ATG GTG CTC GTC GCC ATA 102Pro Cys Asn Ala Pro Arg Trp Val Ser Leu Met Val Leu Val Ala Ile -20 -15 -10GGC ACC GCC GTG ACA GCG GCC GTC AAC CCT GGC GTC GTG GTC AGG ATC 150Gly Thr Ala Val Thr Ala Ala Val Asn Pro Gly Val Val Val Arg Ile -5 1 5TCC CAG AAG GGC CTG GAC TAC GCC AGC CAG CAG GGG ACG GCC GCT CTG 198Ser Gln Lys Gly Leu Asp Tyr Ala Ser Gln Gln Gly Thr Ala Ala Leu 10 15 20 25CAG AAG GAG CTG AAG AGG ATC AAG ATT CCT GAC TAC TCA GAC AGC TTT 246Gln Lys Glu Leu Lys Arg Ile Lys Ile Pro Asp Tyr Ser Asp Ser Phe 30 35 40AAG ATC AAG CAT CTT GGG AAG GGG CAT TAT AGC TTC TAC AGC ATG GAC 294Lys Ile Lys His Leu Gly Lys Gly His Tyr Ser Phe Tyr Ser Met Asp 45 50 55ATC CGT GAA TTC CAG CTT CCC AGT TCC CAG ATA AGC ATG GTG CCC AAT 342Ile Arg Glu Phe Gln Leu Pro Ser Ser Gln Ile Ser Met Val Pro Asn 60 65 70GTG GGC CTT AAG TTC TCC ATC AGC AAC GCC AAT ATC AAG ATC AGC GGG 390Val Gly Leu Lys Phe Ser Ile Ser Asn Ala Asn Ile Lys Ile Ser Gly 75 80 85AAA TGG AAG GCA CAA AAG AGA TTC TTA AAA ATG AGC GGC AAT TTT GAC 438Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Met Ser Gly Asn Phe Asp 90 95 100 105CTG AGC ATA GAA GGC ATG TCC ATT TCG GCT GAT CTG AAG CTG GGC AGT 486Leu Ser Ile Glu Gly Met Ser Ile Ser Ala Asp Leu Lys Leu Gly Ser 110 115 120AAC CCC ACG TCA GGC AAG CCC ACC ATC ACC TGC TCC AGC TGC AGC AGC 534Asn Pro Thr Ser Gly Lys Pro Thr Ile Thr Cys Ser Ser Cys Ser Ser 125 130 135CAC ATC AAC AGT GTC CAC GTG CAC ATC TCA AAG AGC AAA GTC GGG TGG 582His Ile Asn Ser Val His Val His Ile Ser Lys Ser Lys Val Gly Trp 140 145 150CTG ATC CAA CTC TTC CAC AAA AAA ATT GAG TCT GCG CTT CGA AAC AAG 630Leu Ile Gln Leu Phe His Lys Lys Ile Glu Ser Ala Leu Arg Asn Lys 155 160 165ATG AAC AGC CAG GTC TGC GAG AAA GTG ACC AAT TCT GTA TCC TCC AAG 678Met Asn Ser Gln Val Cys Glu Lys Val Thr Asn Ser Val Ser Ser Lys170 175 180 185CTG CAA CCT TAT TTC CAG ACT CTG CCA GTA ATG ACC AAA ATA GAT TCT 726Leu Gln Pro Tyr Phe Gln Thr Leu Pro Val Met Thr Lys Ile Asp Ser 190 195 200GTG GCT GGA ATC AAC TAT GGT CTG GTG GCA CCT CCA GCA ACC ACG GCT 774Val Ala Gly Ile Asn Tyr Gly Leu Val Ala Pro Pro Ala Thr Thr Ala 205 210 215GAG ACC CTG GAT GTA CAG ATG AAG GGG GAG TTT TAC AGT GAG AAC CAC 822Glu Thr Leu Asp Val Gln Met Lys Gly Glu Phe Tyr Ser Glu Asn His 220 225 230CAC AAT CCA CCT CCC TTT GCT CCA CCA GTG ATG GAG TTT CCC GCT GCC 870His Asn Pro Pro Pro Phe Ala Pro Pro Val Met Glu Phe Pro Ala Ala 235 240 245CAT GAC CGC ATG GTA TAC CTG GGC CTC TCA GAC TAC TTC TTC AAC ACA 918His Asp Arg Met Val Tyr Leu Gly Leu Ser Asp Tyr Phe Phe Asn Thr250 255 260 265GCC GGG CTT GTA TAC CAA GAG GCT GGG GTC TTG AAG ATG ACC CTT AGA 966Ala Gly Leu Val Tyr Gln Glu Ala Gly Val Leu Lys Met Thr Leu Arg 270 275 280GAT GAC ATG ATT CCA AAG GAG TCC AAA TTT CGA CTG ACA ACC AAG TTC 1014Asp Asp Met Ile Pro Lys Glu Ser Lys Phe Arg Leu Thr Thr Lys Phe 285 290 295TTT GGA ACC TTC CTA CCT GAG GTG GCC AAG AAG TTT CCC AAC ATG AAG 1062Phe Gly Thr Phe Leu Pro Glu Val Ala Lys Lys Phe Pro Asn Met Lys 300 305 310ATA CAG ATC CAT GTC TCA GCC TCC ACC CCG CCA CAC CTG TCT GTG CAG 1110Ile Gln Ile His Val Ser Ala Ser Thr Pro Pro His Leu Ser Val Gln 315 320 325CCC ACC GGC CTT ACC TTC TAC CCT GCC GTG GAT GTC CAG GCC TTT GCC 1158Pro Thr Gly Leu Thr Phe Tyr Pro Ala Val Asp Val Gln Ala Phe Ala330 335 340 345GTC CTC CCC AAC TCC TCC CTG GCT TCC CTC TTC CTG ATT GGC ATG CAC 1206Val Leu Pro Asn Ser Ser Leu Ala Ser Leu Phe Leu Ile Gly Met His 350 355 360ACA ACT GGT TCC ATG GAG GTC AGC GCC GAG TCC AAC AGG CTT GTT GGA 1254Thr Thr Gly Ser Met Glu Val Ser Ala Glu Ser Asn Arg Leu Val Gly 365 370 375GAG CTC AAG CTG GAT AGG CTG CTC CTG GAA CTG AAG CAC TCA AAT ATT 1302Glu Leu Lys Leu Asp Arg Leu Leu Leu Glu Leu Lys His Ser Asn Ile 380 385 390GGC CCC TTC CCG GTT GAA TTG CTG CAG GAT ATC ATG AAC TAC ATT GTA 1350Gly Pro Phe Pro Val Glu Leu Leu Gln Asp Ile Met Asn Tyr Ile Val 395 400 405CCC ATT CTT GTG CTG CCC AGG GTT AAC GAG AAA CTA CAG AAA GGC TTC 1398Pro Ile Leu Val Leu Pro Arg Val Asn Glu Lys Leu Gln Lys Gly Phe410 415 420 425CCT CTC CCG ACG CCG GCC AGA GTC CAG CTC TAC AAC GTA GTG CTT CAG 1446Pro Leu Pro Thr Pro Ala Arg Val Gln Leu Tyr Asn Val Val Leu Gln 430 435 440CCT CAC CAG AAC TTC CTG CTG TTC GGT GCA GAC GTT GTC TAT AAA 1491Pro His Gln Asn Phe Leu Leu Phe Gly Ala Asp Val Val Tyr Lys 445 450 455TGAAGGCACC AGGGGTGCCG GGGGCTGTCA GCCGCACCTG TTCCTGATGG GCTGTGGGGC 1551ACCGGCTGCC TTTCCCCAGG GAATCCTCTC CAGATCTTAA CCAAGAGCCC CTTGCAAACT 1611TCTTCGACTC AGATTCAGAA ATGATCTAAA CACGAGGAAA CATTATTCAT TGGAAAAGTG 1671CATGGTGTGT ATTTTAGGGA TTATGAGCTT CTTTCAAGGG CTAAGGCTGC AGAGATATTT 1731CCTCCAGGAA TCGTGTTTCA ATTGTAACCA AGAAATTTCC ATTTGTGCTT CATGAAAAAA 1791AACTTCTGGT TTTTTTCATG TG 1813 487 amino acids amino acid linear protein 2Met Arg Glu Asn Met Ala Arg Gly Pro Cys Asn Ala Pro Arg Trp Val-31 -30 -25 -20Ser Leu Met Val Leu Val Ala Ile Gly Thr Ala Val Thr Ala Ala Val-15 -10 -5 1Asn Pro Gly Val Val Val Arg Ile Ser Gln Lys Gly Leu Asp Tyr Ala 5 10 15Ser Gln Gln Gly Thr Ala Ala Leu Gln Lys Glu Leu Lys Arg Ile Lys 20 25 30Ile Pro Asp Tyr Ser Asp Ser Phe Lys Ile Lys His Leu Gly Lys Gly 35 40 45His Tyr Ser Phe Tyr Ser Met Asp Ile Arg Glu Phe Gln Leu Pro Ser 50 55 60 65Ser Gln Ile Ser Met Val Pro Asn Val Gly Leu Lys Phe Ser Ile Ser 70 75 80Asn Ala Asn Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe 85 90 95Leu Lys Met Ser Gly Asn Phe Asp Leu Ser Ile Glu Gly Met Ser Ile 100 105 110Ser Ala Asp Leu Lys Leu Gly Ser Asn Pro Thr Ser Gly Lys Pro Thr 115 120 125Ile Thr Cys Ser Ser Cys Ser Ser His Ile Asn Ser Val His Val His130 135 140 145Ile Ser Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys 150 155 160Ile Glu Ser Ala Leu Arg Asn Lys Met Asn Ser Gln Val Cys Glu Lys 165 170 175Val Thr Asn Ser Val Ser Ser Lys Leu Gln Pro Tyr Phe Gln Thr Leu 180 185 190Pro Val Met Thr Lys Ile Asp Ser Val Ala Gly Ile Asn Tyr Gly Leu 195 200 205Val Ala Pro Pro Ala Thr Thr Ala Glu Thr Leu Asp Val Gln Met Lys210 215 220 225Gly Glu Phe Tyr Ser Glu Asn His His Asn Pro Pro Pro Phe Ala Pro 230 235 240Pro Val Met Glu Phe Pro Ala Ala His Asp Arg Met Val Tyr Leu Gly 245 250 255Leu Ser Asp Tyr Phe Phe Asn Thr Ala Gly Leu Val Tyr Gln Glu Ala 260 265 270Gly Val Leu Lys Met Thr Leu Arg Asp Asp Met Ile Pro Lys Glu Ser 275 280 285Lys Phe Arg Leu Thr Thr Lys Phe Phe Gly Thr Phe Leu Pro Glu Val290 295 300 305Ala Lys Lys Phe Pro Asn Met Lys Ile Gln Ile His Val Ser Ala Ser 310 315 320Thr Pro Pro His Leu Ser Val Gln Pro Thr Gly Leu Thr Phe Tyr Pro 325 330 335Ala Val Asp Val Gln Ala Phe Ala Val Leu Pro Asn Ser Ser Leu Ala 340 345 350Ser Leu Phe Leu Ile Gly Met His Thr Thr Gly Ser Met Glu Val Ser 355 360 365Ala Glu Ser Asn Arg Leu Val Gly Glu Leu Lys Leu Asp Arg Leu Leu370 375 380 385Leu Glu Leu Lys His Ser Asn Ile Gly Pro Phe Pro Val Glu Leu Leu 390 395 400Gln Asp Ile Met Asn Tyr Ile Val Pro Ile Leu Val Leu Pro Arg Val 405 410 415Asn Glu Lys Leu Gln Lys Gly Phe Pro Leu Pro Thr Pro Ala Arg Val 420 425 430Gln Leu Tyr Asn Val Val Leu Gln Pro His Gln Asn Phe Leu Leu Phe 435 440 445Gly Ala Asp Val Val Tyr Lys450 455 29 amino acids amino acid linear peptide misc_feature “Domain I” 3Ala Ser Gln Gln Gly Thr Ala Ala Leu Gln Lys Glu Leu Lys Arg Ile1 5 10 15Lys Ile Pro Asp Tyr Ser Asp Ser Phe Lys Ile Lys His 20 25 30 amino acids amino acid linear peptide misc_feature “BPI.14” 4Gly Thr Ala Ala Leu Gln Lys Glu Leu Lys Arg Ile Lys Ile Pro Asp1 5 10 15Tyr Ser Asp Ser Phe Lys Ile Lys His Leu Gly Lys Gly His 20 25 30 22 amino acids amino acid linear peptide misc_feature “BPI.4” 5Leu Gln Lys Glu Leu Lys Arg Ile Lys Ile Pro Asp Tyr Ser Asp Ser1 5 10 15Phe Lys Ile Lys His Leu 20 15 amino acids amino acid linear peptide misc_feature “BPI.1” 6Gln Gln Gly Thr Ala Ala Leu Gln Lys Glu Leu Lys Arg Ile Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.54” 7Gly Thr Ala Ala Leu Gln Lys Glu Leu Lys Arg Ile Lys Ile Pro1 5 10 15 35 amino acids amino acid linear peptide misc_feature “Domain II” 8Ser Ser Gln Ile Ser Met Val Pro Asn Val Gly Leu Lys Phe Ser Ile1 5 10 15Ser Asn Ala Asn Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg 20 25 30Phe Leu Lys 35 15 amino acids amino acid linear peptide misc_feature “BPI.2” 9Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys1 5 10 15 10 amino acids amino acid linear peptide misc_feature “BPI.8” 10Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys1 5 10 16 amino acids amino acid linear peptide misc_feature “BPI.58” 11Cys Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys1 5 10 15 17 amino acids amino acid linear peptide misc_feature “BPI.65 oxidized” 12Cys Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys1 5 10 15Cys 27 amino acids amino acid linear peptide misc_feature “BPI.3” 13Asn Val Gly Leu Lys Phe Ser Ile Ser Asn Ala Asn Ile Lys Ile Ser1 5 10 15Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys 20 25 28 amino acids amino acid linear peptide misc_feature “Domain III” 14Val His Val His Ile Ser Lys Ser Lys Val Gly Trp Leu Ile Gln Leu1 5 10 15Phe His Lys Lys Ile Glu Ser Ala Leu Arg Asn Lys 20 25 13 amino acids amino acid linear peptide misc_feature “BPI.11” 15Lys Ser Lys Val Trp Leu Ile Gln Leu Phe His Lys Lys1 5 10 29 amino acids amino acid linear peptide misc_feature “BPI.12” 16Ser Val His Val His Ile Ser Lys Ser Lys Val Gly Trp Leu Ile Gln1 5 10 15Leu Phe His Lys Lys Ile Glu Ser Ala Leu Arg Asn Lys 20 25 14 amino acids amino acid linear peptide misc_feature “BPI.13” 17Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys1 5 10 15 amino acids amino acid linear peptide misc_feature “BPI.15” 18Ala Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.16” 19Ile Ala Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.17” 20Ile Lys Ala Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.18” 21Ile Lys Ile Ala Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.19” 22Ile Lys Ile Ser Ala Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.20” 23Ile Lys Ile Ser Gly Ala Trp Lys Ala Gln Lys Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.21” 24Ile Lys Ile Ser Gly Lys Ala Lys Ala Gln Lys Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.22” 25Ile Lys Ile Ser Gly Lys Trp Ala Ala Gln Lys Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.23” 26Ile Lys Ile Ser Gly Lys Trp Lys Ala Ala Lys Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.24” 27Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Ala Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.25” 28Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Ala Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.26” 29Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Ala Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.27” 30Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Ala Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.28” 31Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Ala1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.59” 32Ile Lys Ile Ser Gly Ala Trp Ala Ala Gln Lys Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.45” 33Ile Lys Ile Ser Gly Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.60” 34Ile Ala Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Ala1 5 10 15 14 amino acids amino acid linear peptide misc_feature “BPI.31” 35Ala Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.32” 36Lys Ala Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.33” 37Lys Ser Ala Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.34” 38Lys Ser Lys Ala Gly Trp Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.35” 39Lys Ser Lys Val Ala Trp Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.36” 40Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.37” 41Lys Ser Lys Val Gly Trp Ala Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.38” 42Lys Ser Lys Val Gly Trp Leu Ala Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.39” 43Lys Ser Lys Val Gly Trp Leu Ile Ala Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.40” 44Lys Ser Lys Val Gly Trp Leu Ile Gln Ala Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.41” 45Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Ala His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.42” 46Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe Ala Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.43” 47Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Ala Lys 1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.44” 48Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Ala1 5 10 15 amino acids amino acid linear peptide misc_feature “BPI.56” 49Ile Lys Ile Ser Gly Lys Trp Lys Ala Lys Gln Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.61” 50Ile Lys Ile Ser Gly Lys Phe Lys Ala Gln Lys Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.66” Modified-site /label= D-Trp /note= “The amino acid at position 7 is D-tryptophan” 51Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.67” Modified-site 6..8 /label= Substituted-Ala /note= “The alanine at position 7 is beta-1-naphthyl-substituted” 52Ile Lys Ile Ser Gly Lys Ala Lys Ala Gln Lys Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.9” 53Lys Arg Phe Leu Lys Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys1 5 10 15 24 amino acids amino acid linear peptide misc_feature “BPI.30” 54Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Lys Ser Lys Val Gly Trp1 5 10 15Leu Ile Gln Leu Phe His Lys Lys 20 29 amino acids amino acid linear peptide misc_feature “BPI.63” 55Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Lys1 5 10 15Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys 20 25 20 amino acids amino acid linear peptide misc_feature “BPI.7” 56Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Lys Trp Lys Ala Gln Lys1 5 10 15Arg Phe Leu Lys 20 25 amino acids amino acid linear peptide misc_feature “BPI.10.1” 57Lys Arg Phe Leu Lys Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Lys1 5 10 15Trp Lys Ala Gln Lys Arg Phe Leu Lys 20 25 28 amino acids amino acid linear peptide misc_feature “BPI.29” 58Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys Lys Ser1 5 10 15Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys 20 25 20 amino acids amino acid linear peptide misc_feature “BPI.46” 59Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys Lys Trp Lys Ala Gln Lys1 5 10 15Arg Phe Leu Lys 20 20 amino acids amino acid linear peptide misc_feature “BPI.47” 60Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Lys Trp Lys Ala Ala Ala1 5 10 15Arg Phe Leu Lys 20 20 amino acids amino acid linear peptide misc_feature “BPI.48” 61Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys Lys Trp Lys Ala Ala Ala1 5 10 15Arg Phe Leu Lys 20 30 amino acids amino acid linear peptide misc_feature “BPI.69” 62Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys Lys Trp Lys Ala Ala Ala1 5 10 15Arg Phe Leu Lys Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys 20 25 30 21 amino acids amino acid linear peptide misc_feature “BPI.55” 63Gly Trp Leu Ile Gln Leu Phe His Lys Lys Ile Glu Ser Ala Leu Arg1 5 10 15Asn Lys Met Asn Ser 20 15 amino acids amino acid linear peptide misc_feature “BPI.73” 64Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Phe Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.70” Modified-site 8..10 /label= Substituted-Ala /note= “The alanine at position 7 is beta-3-pyridyl-substituted” 65Ile Lys Ile Ser Gly Lys Ala Lys Ala Gln Lys Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.71” Modified-site 13..15 /label= Substituted-Ala /note= “The alanine at position 13 is beta-3-pyridyl-substituted” 66Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Ala Leu Lys1 5 10 15 26 amino acids amino acid linear peptide misc_feature “BPI.10.2” 67Gln Lys Arg Phe Leu Lys Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys1 5 10 15Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys 20 25 17 amino acids amino acid linear peptide misc_feature “BPI.72” Modified-site 1..3 /label= D-alanine /note= “The position 1 and position 2 alanine residues are both D-alanine” 68Ala Ala Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu1 5 10 15Lys 22 amino acids amino acid linear peptide misc_feature “BPI.5” 69Val His Val His Ile Ser Lys Ser Lys Val Gly Trp Leu Ile Gln Leu1 5 10 15Phe His Lys Lys Ile Glu 20 17 amino acids amino acid linear peptide misc_feature “BPI.65 reduced” Disulfide-bond 1..17 70Cys Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys1 5 10 15Cys 24 amino acids amino acid linear peptide misc_feature “BPI.74” 71Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys Lys Trp1 5 10 15Lys Ala Gln Lys Arg Phe Leu Lys 20 15 amino acids amino acid linear peptide misc_feature “BPI.76” Modified-site 10..12 /label= D-Phe /note= “The amino acid at position 11 is D-phenylalanine” 72Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Phe Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.77” 73Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Trp Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.79” 74Ile Lys Ile Ser Gly Lys Trp Lys Ala Lys Lys Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.80” Modified-site 10..12 /label= Substituted-Ala /note= “The alanine at position 11 is beta-1-naphthyl-substituted” 75Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Ala Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.81” 76Ile Lys Ile Ser Gly Lys Trp Lys Ala Phe Lys Arg Phe Leu Lys1 5 10 15 14 amino acids amino acid linear peptide misc_feature “BPI.82” 77Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Trp His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.83” Modified-site 10..12 /label= Substituted-Ala /note= “The alanine at position 6 is beta-1-naphthyl-substituted” 78Lys Ser Lys Val Gly Ala Lys Ile Gln Leu Phe His Lys Lys1 5 10 15 amino acids amino acid linear peptide misc_feature “BPI.84” Modified-site 6..8 /label= Substituted-Ala /note= “The alanine at position 7 is beta-1-naphthyl-substituted” 79Ile Lys Ile Ser Gly Lys Ala Lys Ala Gln Phe Arg Phe Leu Lys1 5 10 15 14 amino acids amino acid linear peptide misc_feature “BPI.85” 80Lys Ser Lys Val Leu Trp Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.86” 81Lys Ser Lys Val Gly Trp Leu Ile Leu Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.87” 82Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe Leu Lys Lys1 5 10 15 amino acids amino acid linear peptide misc_feature “BPI.88” 83Ile Lys Ile Ser Gly Lys Trp Lys Ala Phe Phe Arg Phe Leu Lys1 5 10 15 24 amino acids amino acid linear peptide misc_feature “BPI.98” Modified-site /label= Substituted-Trp /note= “The alanine at position 2 is beta-1-naphthyl-substituted” 84Lys Trp Lys Ala Gln Phe Arg Phe Leu Lys Lys Ser Lys Val Gly Trp1 5 10 15Leu Ile Phe Leu Phe His Lys Lys 20 15 amino acids amino acid linear peptide misc_feature “BPI.89” Modified-site 6..8 /label= Substituted-Ala /note= “The alanine at position 7 is beta-1-naphthyl-substituted” 85Ile Lys Ile Ser Gly Lys Ala Lys Ala Phe Lys Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.90” Modified-site 6..8 /label= Substituted-Ala /note= “The alanine at position 7 is beta-1-naphthyl-substituted” 86Ile Lys Ile Ser Gly Lys Ala Lys Ala Phe Phe Arg Phe Leu Lys1 5 10 15 14 amino acids amino acid linear peptide misc_feature “BPI.91” 87Lys Ser Lys Val Gly Trp Leu Ile Phe Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.92” 88Lys Ser Lys Val Gly Trp Leu Ile Lys Leu Phe His Lys Lys1 5 10 29 amino acids amino acid linear peptide misc_feature “BPI.93” Modified-site 6..8 /label= Substituted-Ala /note= “The alanine at position 7 is beta-1-naphthyl-substituted” 89Ile Lys Ile Ser Gly Lys Ala Lys Ala Gln Phe Arg Phe Leu Lys Lys1 5 10 15Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys 20 25 14 amino acids amino acid linear peptide misc_feature “BPI.94” 90Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe Phe Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.95” 91Lys Ser Lys Val Phe Trp Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.96” 92Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Phe1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.97” 93Lys Ser Lys Val Lys Trp Leu Ile Gln Leu Phe His Lys Lys1 5 10 30 amino acids amino acid linear peptide misc_feature “BPI.99” 94Lys Trp Lys Ala Gln Trp Arg Phe Leu Lys Lys Trp Lys Ala Gln Trp1 5 10 15Arg Phe Leu Lys Lys Trp Lys Ala Gln Trp Arg Phe Leu Lys 20 25 30 14 amino acids amino acid linear peptide misc_feature “BPI.100” 95Lys Ser Lys Val Lys Trp Leu Ile Lys Leu Phe His Lys Lys1 5 10 28 amino acids amino acid linear peptide misc_feature “BPI.101” 96Lys Ser Lys Val Lys Trp Leu Ile Lys Leu Phe Phe Lys Phe Lys Ser1 5 10 15Lys Val Lys Trp Leu Ile Lys Leu Phe Phe Lys Phe 20 25 24 amino acids amino acid linear peptide misc_feature “BPI.102” 97Lys Trp Lys Ala Gln Phe Arg Phe Leu Lys Lys Ser Lys Val Gly Trp1 5 10 15Leu Ile Leu Leu Phe His Lys Lys 20 16 amino acids amino acid linear peptide misc_feature “BPI.57” 98Cys Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Pro Leu Cys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.75” 99Ile Lys Lys Arg Ala Ile Ser Phe Leu Gly Lys Lys Trp Gln Lys1 5 10 15 20 amino acids amino acid linear peptide misc_feature “BPI.282” 100Lys Trp Lys Ala Phe Phe Arg Phe Leu Lys Lys Trp Lys Ala Phe Phe1 5 10 15Arg Phe Leu Lys 20 16 amino acids amino acid linear peptide misc_feature “BPI.103” 101Ile Lys Ile Ser Gly Lys Trp Lys Ala Trp Lys Arg Phe Leu Lys Lys1 5 10 15 14 amino acids amino acid linear peptide misc_feature “BPI.104” 102Lys Ser Lys Val Gly Trp Leu Ile Ser Leu Phe His Lys Lys1 5 10 16 amino acids amino acid linear peptide misc_feature “BPI.105” Modified-site 13 /label= Substituted-Ala /note= “The alanine at position 13 is beta-1- naphthyl-substituted.” 103Ile Lys Ile Ser Gly Lys Trp Lys Ala Trp Lys Arg Ala Leu Lys Lys1 5 10 15 14 amino acids amino acid linear peptide misc_feature “BPI.106” 104Lys Ser Lys Val Gly Trp Leu Ile Thr Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.107” 105Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe Trp Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.108” 106Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Trp1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.109” Modified-site 11 /label= Substituted-Ala /note= “The alanine at position 11 is beta-1- naphthyl-substituted.” 107Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Ala His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.110” Modified-site 12 /label= Substituted-Ala /note= “The alanine at position 12 is beta-1- naphthyl-substituted.” 108Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe Ala Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.111” Modified-site 14 /label= Substituted-Ala /note= “The alanine at position 14 is beta-1- naphthyl-substituted.” 109Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Ala1 5 10 15 amino acids amino acid linear peptide misc_feature “BPI.112” Modified-site /label= Substituted-Ala /note= “The alanine at position 7 is beta-1- naphthyl-substituted.” Modified-site 11 /label= Substituted-Ala /note= “The alanine at position 11 is beta-1- naphthyl-substituted.” 110Ile Lys Ile Ser Gly Lys Ala Lys Ala Gln Ala Arg Phe Leu Lys1 5 10 15 14 amino acids amino acid linear peptide misc_feature “BPI.113” 111Lys Ser Lys Val Gly Trp Leu Ile Gln Phe Phe His Lys Lys1 5 10 15 amino acids amino acid linear peptide misc_feature “BPI.114” 112Lys Trp Gln Leu Arg Ser Lys Gly Lys Ile Lys Ile Phe Lys Ala1 5 10 15 14 amino acids amino acid linear peptide misc_feature “BPI.116” Modified-site /label= Substituted-Ala /note= “The alanine at position 6 is beta-1- naphthyl-substituted.” 113Lys Ser Lys Val Lys Ala Leu Ile Gln Leu Phe His Lys Lys1 5 10 15 amino acids amino acid linear peptide misc_feature “BPI.119” Modified-site /label= Substituted-Ala /note= “The alanine at position 7 is beta-1- naphthyl-substituted.” Modified-site 10 /label= Substituted-Ala /note= “The alanine at position 10 is beta-1- naphthyl-substituted.” 114Ile Lys Ile Ser Gly Lys Ala Lys Ala Ala Lys Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.120” 115Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Lys Leu Lys 1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.121” Modified-site 10 /label= Substituted-Ala /note= “The alanine at position 10 is beta-1- naphthyl-substituted.” Modified-site 11 /label= Substituted-Ala /note= “The alanine at position 11 is beta-1- naphthyl-substituted.” 116Ile Lys Ile Ser Gly Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.122” Modified-site /label= Substituted-Ala /note= “The alanine at position 7 is beta-1- naphthyl-substituted.” Modified-site 10 /label= Substituted-Ala /note= “The alanine at position 10 is beta-1- naphthyl-substituted.” Modified-site 11 /label= Substituted-Ala /note= “The alanine at position 11 is beta-1- naphthyl-substituted.” 117Ile Lys Ile Ser Gly Lys Ala Lys Ala Ala Ala Arg Phe Leu Lys1 5 10 15 14 amino acids amino acid linear peptide misc_feature “BPI.123” Modified-site /label= Substituted-Phe /note= “The phenylalanine at position 9 is p-amino-substituted.” 118Lys Ser Lys Val Gly Trp Leu Ile Phe Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.124” 119Lys Ser Lys Val Lys Trp Leu Ile Gln Leu Trp His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.125” 120Lys Ser Lys Val Gly Trp Leu Ile Tyr Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.126” Modified-site /label= D-Trp /note= “The amino acid at position 6 is D-tryptophan.” 121Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.127” 122Lys Ser Lys Val Gly Phe Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.128” Modified-site /label= D-Phe /note= “The amino acid at position 6 is D-phenylalanine.” 123Lys Ser Lys Val Gly Phe Leu Ile Gln Leu Pro His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.129” Modified-site /label= Substituted-Ala /note= “The alanine at position 6 is D-1-beta-1-naphthyl- substituted.” 124Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys 1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.130” Modified-site /label= Substituted-Ala /note= “The alanine at position 6 is 2-beta-1-naphthyl- substituted.” 125Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.131” Modified-site /label= Substituted-Ala /note= “The alanine at position 6 is D-2-beta-1-naphthyl- substituted.” 126Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.132” Modified-site /label= Substituted-Ala /note= “The alanine at position 6 is pyridyl-substituted.” 127Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.133” Modified-site /label= Substituted-Phe /note= “The phenylalanine at position 6 is para-amino- substituted.” 128Lys Ser Lys Val Gly Phe Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.134” Modified-site /label= Substituted-Phe /note= “The phenylalanine at position 5 is para-amino-substituted.” 129Lys Ser Lys Val Phe Trp Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.135” 130Lys Ser Lys Val Gly Lys Leu Ile Gln Leu Pro His Lys Lys1 5 10 15 amino acids amino acid linear peptide misc_feature “BPI.136” 131Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Glu Arg Phe Leu Lys1 5 10 15 16 amino acids amino acid linear peptide misc_feature “BPI.137” 132Cys Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys Cys1 5 10 15 14 amino acids amino acid linear peptide misc_feature “BPI.138” 133Lys Ser Lys Val Lys Phe Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.139” 134Lys Ser Lys Val Gly Tyr Leu Ile Gln Leu Phe His Lys Lys1 5 10 7 amino acids amino acid linear peptide misc_feature “BPI.140” Modified-site /label= Substituted-Ala /note= “The alanine at position 1 is beta-1-naphthyl-substituted.” Modified-site /label= Substituted-Ala /note= “The alanine at position 2 is beta-1-naphthyl-substituted.” 135Ala Ala Arg Phe Leu Lys Phe1 5 15 amino acids amino acid linear peptide misc_feature “BPI.141” 136Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Trp Leu Lys1 5 10 15 14 amino acids amino acid linear peptide misc_feature “BPI.142” 137Lys Ser Lys Val Gly Trp Leu Ile Gln Trp Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.143” Modified-site 10 /label= Substituted-Ala /note= “The alanine at position 10 is beta-1-naphthyl-substituted.” 138Lys Ser Lys Val Gly Trp Leu Ile Gln Ala Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.144” Modified-site /label= Substituted-Ala /note= “The alanine at position 6 is cyclohexyl-substituted.” 139Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys1 5 10 24 amino acids amino acid linear peptide misc_feature “BPI.145” 140Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys Lys Ser Lys Val Gly Trp1 5 10 15Leu Ile Gln Leu Phe His Lys Lys 20 14 amino acids amino acid linear peptide misc_feature “BPI.146” Modified-site 12 /label= Substituted-Ala /note= “The alanine at position 12 is beta-1-naphthyl-substituted.” Modified-site 14 /label= Substituted-Ala /note= “The alanine at position 14 is beta-1-naphthyl-substituted.” 141Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe Ala Lys Ala1 5 10 15 amino acids amino acid linear peptide misc_feature “BPI.147” 142Ile Lys Ile Ser Gly Lys Trp Lys Ala Glu Lys Lys Phe Leu Lys1 5 10 15 14 amino acids amino acid linear peptide misc_feature “BPI.148” Modified-site /label= Substituted-Ala /note= “The alanine at position 6 is beta-1-naphthyl-substituted.” Modified-site 12 /label= Substituted-Ala /note= “The alanine at position 12 is beta-1-naphthyl-substituted.” 143Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe Ala Lys Lys1 5 10 24 amino acids amino acid linear peptide misc_feature “BPI.149” 144Lys Trp Lys Val Phe Lys Lys Ile Glu Lys Lys Ser Lys Val Gly Trp1 5 10 15Leu Ile Gln Leu Phe His Lys Lys 20 20 amino acids amino acid linear peptide misc_feature “BPI.150” 145Lys Trp Ala Phe Ala Lys Lys Gln Lys Lys Arg Leu Lys Arg Gln Trp1 5 10 15Leu Lys Lys Phe 20 30 amino acids amino acid linear peptide misc_feature “BPI.153” 146Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Lys Trp Lys Ala Gln Lys1 5 10 15Arg Phe Leu Lys Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys 20 25 30 20 amino acids amino acid linear peptide misc_feature “BPI.154” Modified-site /label= Substituted-Ala /note= “Position 5 is beta-1-naphthyl-substituted.” Modified-site /label= Substituted-Ala /note= “Position 6 is beta-1-naphthyl-substituted.” 147Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys Lys Trp Lys Ala Gln Lys1 5 10 15Arg Phe Leu Lys 20 20 amino acids amino acid linear peptide misc_feature “BPI.155” Modified-site 15 /label= Substituted-Ala /note= “Position 15 is beta-1-naphthyl-substituted.” Modified-site 16 /label= Substituted-Ala /note= “Position 16 is beta-1-naphthyl-substituted.” 148Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Lys Trp Lys Ala Ala Ala1 5 10 15Arg Phe Leu Lys 20 20 amino acids amino acid linear peptide misc_feature “BPI.156” Modified-site /label= Substituted-Ala /note= “Position 5 is beta-1-naphthyl-substituted.” Modified-site /label= Substituted-Ala /note= “Position 6 is beta-1-naphthyl-substituted.” Modified-site 15 /label= Substituted-Ala /note= “Position 15 is beta-1-naphthyl-substituted.” Modified-site 16 /label= Substituted-Ala /note= “Position 16 is beta-1-naphthyl-substituted.” 149Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys Lys Trp Lys Ala Ala Ala1 5 10 15Arg Phe Leu Lys 20 30 amino acids amino acid linear peptide misc_feature “BPI.157” Modified-site /label= Substituted-Ala /note= “Position 5 is beta-1-naphthyl-substituted.” Modified-site /label= Substituted-Ala /note= “Position 6 is beta-1-naphthyl-substituted.” Modified-site 15 /label= Substituted-Ala /note= “Position 15 is beta-1-naphthyl-substituted.” Modified-site 16 /label= Substituted-Ala /note= “Position 16 is beta-1-naphthyl-substituted.” Modified-site 25 /label= Substituted-Ala /note= “Position 25 is beta-1-naphthyl-substituted.” Modified-site 26 /label= Substituted-Ala /note= “Position 26 is beta-1-naphthyl-substituted.” 150Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys Lys Trp Lys Ala Ala Ala1 5 10 15Arg Phe Leu Lys Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys 20 25 30 29 amino acids amino acid linear peptide misc_feature “BPI.158” Modified-site 10 /label= Substituted-Ala /note= “Position 10 is beta-1-naphthyl-substituted.” Modified-site 11 /label= Substituted-Ala /note= “Position 11 is beta-1-naphthyl-substituted.” 151Ile Lys Ile Ser Gly Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys Lys1 5 10 15Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys 20 25 24 amino acids amino acid linear peptide misc_feature “BPI.159” Modified-site /label= Substituted-Ala /note= “Position 2 is beta-1-naphthyl-substituted.” Modified-site /label= Substituted-Ala /note= “Position 6 is beta-1-naphthyl-substituted.” 152Lys Ala Lys Ala Gln Ala Arg Phe Leu Lys Lys Ser Lys Val Gly Trp1 5 10 15Leu Ile Gln Leu Trp His Lys Lys 20 20 amino acids amino acid linear peptide misc_feature “BPI.160” Modified-site /label= Substituted-Ala /note= “Position 2 is beta-1-naphthyl-substituted.” Modified-site /label= Substituted-Ala /note= “Position 6 is beta-1-naphthyl-substituted.” Modified-site 12 /label= Substituted-Ala /note= “Position 12 is beta-1-naphthyl-substituted.” Modified-site 16 /label= Substituted-Ala /note= “Position 16 is beta-1-naphthyl-substituted.” 153Lys Ala Lys Ala Gln Ala Arg Phe Leu Lys Lys Ala Lys Ala Gln Ala1 5 10 15Arg Phe Leu Lys 20 14 amino acids amino acid linear peptide misc_feature “BPI.161” 154Lys Ser Lys Val Lys Ala Leu Ile Gln Leu Phe His Lys Lys1 5 10 24 amino acids amino acid linear peptide misc_feature “BPI.162” 155Lys Trp Lys Ala Gln Trp Arg Phe Leu Lys Lys Ser Lys Val Gly Trp1 5 10 15Leu Ile Gln Leu Phe His Lys Lys 20 20 amino acids amino acid linear peptide misc_feature “BPI.163” 156Lys Trp Lys Ala Gln Trp Arg Phe Leu Lys Lys Trp Lys Ala Gln Trp1 5 10 15Arg Phe Leu Lys 20 20 amino acids amino acid linear peptide misc_feature “BPI.164” Modified-site /label= Substituted-Ala /note= “Position 5 is beta-1-naphthyl-substituted.” Modified-site 15 /label= Substituted-Ala /note= “Position 15 is beta-1-naphthyl-substituted.” 157Lys Trp Lys Ala Ala Lys Arg Phe Leu Lys Lys Trp Lys Ala Ala Lys1 5 10 15Arg Phe Leu Lys 20 20 amino acids amino acid linear peptide misc_feature “BPI.165” Modified-site /label= Substituted-Ala /note= “Position 2 is beta-1-naphthyl-substituted.” Modified-site 12 /label= Substituted-Ala /note= “Position 12 is beta-1-naphthyl-substituted.” 158Lys Ala Lys Ala Gln Phe Arg Phe Leu Lys Lys Ala Lys Ala Gln Phe1 5 10 15Arg Phe Leu Lys 20 14 amino acids amino acid linear peptide misc_feature “BPI.166” 159Lys Ser Lys Val Gly Val Leu Ile Gln Leu Phe His Lys Lys1 5 10 8 amino acids amino acid linear peptide misc_feature “BPI.167” 160Lys Trp Lys Ala Gln Lys Arg Phe1 5 14 amino acids amino acid circular peptide misc_feature “BPI.168” 161Cys Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Met Ser Cys1 5 10 10 amino acids amino acid circular peptide misc_feature “BPI.169” 162Cys Lys Trp Lys Ala Gln Lys Arg Phe Cys1 5 10 15 amino acids amino acid linear peptide misc_feature “BPI.221” Modified-site 13 /label= Substituted-Ala /note= “Position 13 is beta-1-naphthyl-substituted.” 163Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Ala Leu Lys1 5 10 15 14 amino acids amino acid linear peptide misc_feature “BPI.222” Modified-site /label= Substituted-Ala /note= “Position 6 is beta-1-naphthyl-substituted.” Modified-site 14 /label= Substituted-Ala /note= “Position 14 is beta-1-naphthyl-substituted.” 164Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Ala1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.223” Modified-site /label= Substituted-Ala /note= “Position 6 is beta-1-naphthyl-substituted.” Modified-site 10 /label= Substituted-Ala /note= “Position 10 is beta-1-naphthyl-substituted.” 165Lys Ser Lys Val Gly Ala Leu Ile Gln Ala Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.224” Modified-site /label= Substituted-Ala /note= “Position 6 is beta-1-naphthyl-substituted.” Modified-site /label= Substituted-Phe /note= “Position 9 is para-amino-substituted.” 166Lys Ser Lys Val Gly Ala Leu Ile Phe Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.225” Modified-site /label= Substituted-Ala /note= “Position 6 is beta-1-naphthyl-substituted.” Modified-site /label= Substituted-Phe /note= “Position 5 is para-amino-substituted.” 167Lys Ser Lys Val Phe Ala Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.226” Modified-site /label= Substituted-Ala /note= “Position 6 is beta-1-naphthyl-substituted.” 168Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Trp His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.227” Modified-site 10 /label= Substituted-Ala /note= “Position 10 is beta-1-naphthyl-substituted.” Modified-site 14 /label= Substituted-Ala /note= “Position 14 is beta-1-naphthyl-substituted.” 169Lys Ser Lys Val Gly Trp Leu Ile Gln Ala Phe His Lys Ala1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.228” Modified-site /label= Substituted-Phe /note= “Position 9 is para-amino-substituted.” Modified-site 14 /label= Substituted-Ala /note= “Position 14 is beta-1-naphthyl-substituted.” 170Lys Ser Lys Val Gly Trp Leu Ile Phe Leu Phe His Lys Ala1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.229” Modified-site /label= Substituted-Ala /note= “Position 5 is para-amino-substituted.” Modified-site 14 /label= Substituted-Ala /note= “Position 14 is beta-1-naphthyl-substituted.” 171Lys Ser Lys Val Phe Trp Leu Ile Gln Leu Phe His Lys Ala1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.230” Modified-site 14 /label= Substituted-Ala /note= “Position 14 is beta-1-naphthyl-substituted.” 172Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Trp His Lys Ala1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.231” Modified-site 10 /label= Substituted-Ala /note= “Position 10 is beta-1-naphthyl-substituted.” Modified-site 12 /label= Substituted-Ala /note= “Position 12 is beta-1-naphthyl-substituted.” 173Lys Ser Lys Val Gly Trp Leu Ile Gln Ala Phe Ala Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.232” Modified-site /label= Substituted-Phe /note= “Position 9 is para-amino-substituted.” Modified-site 12 /label= Substituted-Ala /note= “Position 12 is beta-1-naphthyl-substituted.” 174Lys Ser Lys Val Gly Trp Leu Ile Phe Leu Phe Ala Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.233” Modified-site /label= Substituted-Phe /note= “Position 5 is para-amino-substituted.” Modified-site 12 /label= Substituted-Ala /note= “Position 12 is beta-1-naphthyl-substituted.” 175Lys Ser Lys Val Phe Trp Leu Ile Gln Leu Phe Ala Lys Lys 1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.234” Modified-site 12 /label= Substituted-Ala /note= “Position 12 is beta-1-naphthyl-substituted.” 176Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Trp Ala Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.235” Modified-site /label= Substituted-Phe /note= “Position 9 is para-amino-substituted.” Modified-site 10 /label= Substituted-Ala /note= “Position 10 is beta-1-naphthyl-substituted.” 177Lys Ser Lys Val Gly Trp Leu Ile Phe Ala Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.236” Modified-site /label= Substituted-Phe /note= “Position 5 is para-amino-substituted.” Modified-site 10 /label= Substituted-Ala /note= “Position 10 is beta-1-naphthyl-substituted.” 178Lys Ser Lys Val Phe Trp Leu Ile Gln Ala Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.237” Modified-site 10 /label= Substituted-Ala /note= “Position 10 is beta-1-naphthyl-substituted.” 179Lys Ser Lys Val Gly Trp Leu Ile Gln Ala Trp His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.238” Modified-site /label= Substituted-Phe /note= “Position 5 is para-amino-substituted.” Modified-site /label= Substituted-Phe /note= “Position 9 is para-amino-substituted.” 180Lys Ser Lys Val Phe Trp Leu Ile Phe Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.239” Modified-site /label= Substituted-Phe /note= “Position 9 is para-amino-substituted.” 181Lys Ser Lys Val Gly Trp Leu Ile Phe Leu Trp His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.240” Modified-site /label= Substituted-Phe /note= “Position 5 is para-amino-substituted.” 182Lys Ser Lys Val Phe Trp Leu Ile Gln Leu Trp His Lys Lys1 5 10 24 amino acids amino acid linear peptide misc_feature “BPI.247” Modified-site /label= Substituted-Ala /note= “Position 2 is beta-1-naphthyl-substituted.” Modified-site /label= Substituted-Ala /note= “Position 6 is beta-1-naphthyl-substituted.” 183Lys Ala Lys Ala Gln Ala Arg Phe Leu Lys Lys Ser Lys Val Gly Trp1 5 10 15Leu Ile Leu Leu Phe His Lys Lys 20 24 amino acids amino acid linear peptide misc_feature “BPI.245” 184Lys Trp Lys Ala Gln Phe Arg Phe Leu Lys Lys Ser Lys Val Gly Trp1 5 10 15Leu Ile Gln Leu Trp His Lys Lys 20 24 amino acids amino acid linear peptide misc_feature “BPI.246” Modified-site 16 /label= Substituted-Ala /note= “Position 16 is D-beta-2-naphthyl-substituted.” 185Lys Trp Lys Ala Gln Phe Arg Phe Leu Lys Lys Ser Lys Val Gly Ala1 5 10 15Leu Ile Gln Leu Phe His Lys Lys 20 24 amino acids amino acid linear peptide misc_feature “BPI.248” Modified-site /label= Substituted-Ala /note= “Position 2 is beta-1-naphthyl-substituted.” Modified-site /label= Substituted-Ala /note= “Position 6 is beta-1-naphthyl-substituted.” Modified-site 16 /label= Substituted-Ala /note= “Position 16 is D-beta-2-naphthyl-substituted.” 186Lys Ala Lys Ala Gln Ala Arg Phe Leu Lys Lys Ser Lys Val Gly Ala1 5 10 15Leu Ile Gln Leu Phe His Lys Lys 20 14 amino acids amino acid linear peptide misc_feature “BPI.242” Modified-site /label= Substituted-Ala /note= “Position 6 is D-beta-2-naphthyl-substituted.” 187Lys Ser Lys Val Gly Ala Leu Ile Leu Leu Phe His Lys Lys1 5 10 28 amino acids amino acid linear peptide misc_feature “BPI.272” 188Lys Ser Lys Val Gly Trp Leu Ile Leu Leu Phe His Lys Lys Lys Ser1 5 10 15Lys Val Gly Trp Leu Ile Leu Leu Phe His Lys Lys 20 25 28 amino acids amino acid linear peptide misc_feature “BPI.275” 189Lys Ser Lys Val Gly Trp Leu Ile Phe Leu Phe His Lys Lys Lys Ser1 5 10 15Lys Val Gly Trp Leu Ile Phe Leu Phe His Lys Lys 20 25 28 amino acids amino acid linear peptide misc_feature “BPI.270” 190Lys Ser Lys Val Gly Trp Leu Ile Leu Leu Phe His Lys Lys Lys Ser1 5 10 15Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys 20 25 28 amino acids amino acid linear peptide misc_feature “BPI.271” 191Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys Lys Ser1 5 10 15Lys Val Gly Trp Leu Ile Leu Leu Phe His Lys Lys 20 25 28 amino acids amino acid linear peptide misc_feature “BPI.273” 192Lys Ser Lys Val Gly Trp Leu Ile Phe Leu Phe His Lys Lys Lys Ser1 5 10 15Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys 20 25 28 amino acids amino acid linear peptide misc_feature “BPI.274” 193Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys Lys Ser1 5 10 15Lys Val Gly Trp Leu Ile Phe Leu Phe His Lys Lys 20 25 24 amino acids amino acid linear peptide misc_feature “BPI.276” 194Lys Trp Lys Ala Gln Phe Arg Phe Leu Lys Lys Ser Lys Val Gly Trp1 5 10 15Leu Ile Phe Leu Phe His Lys Lys 20 14 amino acids amino acid linear peptide misc_feature “BPI.241” 195Lys Ser Lys Val Gly Trp Leu Ile Leu Leu Trp His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.243” Modified-site /label= Substituted-Ala /note= “Position 6 is D-beta-2-naphthyl-substituted.” 196Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Trp His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.244” Modified-site /label= Substituted-Ala /note= “Position 6 is D-beta-2-naphthyl-substituted.” 197Lys Ser Lys Val Gly Ala Leu Ile Leu Leu Trp His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.249” 198Lys Ser Lys Val Gly Gly Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.250” 199Lys Ser Lys Val Gly Leu Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.251” 200Lys Ser Lys Val Gly Ile Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.252” Modified-site /label= D-Ala /note= “The amino acid at position 6 is D-alanine” 201Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.253” Modified-site /label= D-Val /note= “The amino acid at position 6 is D-valine” 202Lys Ser Lys Val Gly Val Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.254” Modified-site /label= beta-Ala /note= “The amino acid at position 6 is beta-alanine” 203Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.255” Modified-site /label= delta-aba /note= “The amino acid at position 6 is delta-aminobutyric acid” 204Lys Ser Lys Val Gly Xaa Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.256” Modified-site /label= gaba /note= “The amino acid at position 6 is gamma-aminobutyric acid” 205Lys Ser Lys Val Gly Xaa Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.257” Modified-site /label= d-methyl-A /note= “The amino acid at position 6 is delta-Methyl-alanine” 206Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.258” Modified-site /label= t-butyl-G /note= “The amino acid at position 6 is tert-butyl-glycine” 207Lys Ser Lys Val Gly Gly Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.259” Modified-site /label= N-methyl-G /note= “The amino acid at position 6 is N-Methyl-glycine” 208Lys Ser Lys Val Gly Gly Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.260” Modified-site /label= N-methyl-V /note= “The amino acid at position 6 is N-Methyl-valine” 209Lys Ser Lys Val Gly Val Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.261” Modified-site /label= N-methyl-L /note= “The amino acid at position 6 is N-Methyl-leucine” 210Lys Ser Lys Val Gly Leu Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.262” 211Lys Ser Lys Val Gly Trp Leu Ile Asn Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.263” 212Lys Ser Lys Val Gly Trp Leu Ile Glu Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.264” 213Lys Ser Lys Val Gly Trp Leu Ile Asp Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.265” 214Lys Ser Lys Val Gly Trp Leu Ile Lys Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.266” 215Lys Ser Lys Val Lys Val Leu Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.267” 216Lys Ser Lys Val Lys Trp Ala Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.268” 217Lys Ser Lys Val Gly Val Ala Ile Gln Leu Phe His Lys Lys1 5 10 14 amino acids amino acid linear peptide misc_feature “BPI.269” 218Lys Ser Lys Val Lys Val Ala Ile Gln Leu Phe His Lys Lys1 5 10 24 amino acids amino acid linear peptide misc_feature “BPI.277” Modified-site /label= Substituted-Ala /note= “The alanine at position 2 is beta-1-naphthyl-substituted.” 219Lys Ala Lys Ala Gln Phe Arg Phe Leu Lys Lys Ser Lys Val Gly Trp1 5 10 15Leu Ile Leu Leu Phe His Lys Lys 20 15 amino acids amino acid linear peptide misc_feature “BPI.278” 220Ile Lys Ile Ser Gly Lys Trp Lys Ala Ala Trp Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.279” Modified-site 10 /label= Substituted-Ala /note= “The alanine at position 10 is beta-1-naphthyl-substituted.” 221Ile Lys Ile Ser Gly Lys Trp Lys Ala Ala Phe Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.280” 222Ile Lys Ile Ser Gly Lys Trp Lys Ala Ala Phe Arg Phe Leu Lys1 5 10 15 15 amino acids amino acid linear peptide misc_feature “BPI.281” Modified-site 10 /label= Substituted-Ala /note= “The alanine at position 10 is beta-1-naphthyl-substituted.” 223Ile Lys Ile Ser Gly Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys1 5 10 15 12 amino acids amino acid linear peptide misc_feature “BPI.170” 224Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Met Ser1 5 10

Claims

1. A method of treating a human subject subjected to liver surgery comprising administering to said subject an amount of bactericidal permeability-increasing protein (BPI) protein product effective to reduce liver failure.

2. The method of claim 1 wherein the BPI protein product is selected from the group consisting of an N-terminal fragment of BPI having a molecular weight of approximately 21 to 25 kD (rBPI23), the expression product of DNA encoding from amino acid 1 to approximately 193 or 199 of the N-terminal amino acids of BPI holoprotein, wherein the cysteine at residue number 132 is substituted with alanine (rBPI21) rBPI, a dimeric form of rBPI23 or rBPI21 (rBPI42 dimer) and peptides as set out in SEQ ID NOS: 3 through 224.

3. The method of claim 1 wherein the BPI protein product is administered in conjunction with a pharmaceutically-acceptable diluent, adjuvant or carrier.

4. The method of claim 1 wherein the liver surgery comprises liver transplant or liver resection (hepatectomy).